var title_f39_15_40176="Pyogenic granuloma toe";
var content_f39_15_40176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma of the toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40176=[""].join("\n");
var outline_f39_15_40176=null;
var title_f39_15_40177="Toxic epidermolytic erosion";
var content_f39_15_40177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erosions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple shallow erosions are present in areas of sloughed skin in this patient with toxic epidermal necrolysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40177=[""].join("\n");
var outline_f39_15_40177=null;
var title_f39_15_40178="Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)";
var content_f39_15_40178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nonsteroidal-antiinflammatory-drugs-nsaids-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1726698\">",
"      <span class=\"h1\">",
"       What are nonsteroidal antiinflammatory drugs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nonsteroidal anti-inflammatory drugs, also called &ldquo;NSAIDs,&rdquo; are medicines that relieve pain and reduce inflammation. They are one of the most commonly used kinds of medicines.",
"     </p>",
"     <p>",
"      NSAIDs can help people who have conditions that cause ongoing pain, such as arthritis. They can also help people heal more quickly after an injury. But NSAIDs can cause problems of their own, so it&rsquo;s important to take the lowest dose you need for the shortest time.",
"     </p>",
"     <p>",
"      You can buy many NSAIDs without a prescription, including",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (brand name: Aleve&reg;). These same NSAIDs can also be prescribed by a doctor, usually at a higher strength. Plus, there are many other prescription-strength NSAIDs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1726705\">",
"      <span class=\"h1\">",
"       Are all NSAIDs the same?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes and no. All NSAIDs work on the same chemical process in the body, but they do it in different ways. Some NSAIDs need to be taken more often during the day than others to work for certain kinds of pain. And some are more likely than others to cause certain side effects.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1726712\">",
"      <span class=\"h1\">",
"       Are NSAIDs safe for everyone?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. People with certain medical conditions should avoid NSAIDs or use them with care. Talk with your doctor if you use NSAIDs without a prescription (called &ldquo;over-the-counter&rdquo;) on a regular basis to be sure they are safe for you.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If you have an",
"        <strong>",
"         ulcer in your stomach or intestine or you have ever had bleeding in the gut",
"        </strong>",
"        , ask your doctor if NSAIDs are safe for you. Your doctor might suggest that you take an NSAID along with a medicine that can protect your stomach and intestines. That&rsquo;s because NSAIDs can damage your stomach or intestines.",
"       </li>",
"       <li>",
"        If you have",
"        <strong>",
"         heart disease or ever had a stroke",
"        </strong>",
"        , ask your doctor if it is safe to take an NSAID. In people with these problems, NSAIDs can increase the risk of heart attacks and strokes. But if your doctor prescribes low-dose",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        to prevent heart attacks or stroke, you should take it as directed. At low doses, aspirin can actually protect you from these problems. &nbsp;",
"       </li>",
"       <li>",
"        If you have",
"        <strong>",
"         kidney disease, heart failure, cirrhosis, or you take medicines called diuretics",
"        </strong>",
"        (also called &ldquo;water pills&rdquo;), avoid NSAIDs completely. NSAIDs can make heart failure, kidney disease, and cirrhosis worse. NSAIDs can also cause kidney problems in people taking diuretics or certain other medicines to control blood pressure. This can happen in people with very mild kidney disease or in older people.",
"       </li>",
"       <li>",
"        If you have",
"        <strong>",
"         high blood pressure",
"        </strong>",
"        , ask your doctor if NSAIDs are safe for you. NSAIDs can raise blood pressure even in people who are taking medicine for high blood pressure. Experts recommend that people with high blood pressure who need NSAIDs take the lowest possible dose for the shortest amount of time. &nbsp;",
"       </li>",
"       <li>",
"        If you have any",
"        <strong>",
"         disorders that increase the risk of bleeding",
"        </strong>",
"        , ask your doctor if NSAIDs are safe for you.",
"       </li>",
"       <li>",
"        If you",
"        <strong>",
"         are having surgery",
"        </strong>",
"        , ask your doctor if you should stop taking NSAIDs. Most people need to stop NSAIDs, including",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        , a week before surgery to lower the risk of bleeding.",
"       </li>",
"       <li>",
"        If you",
"        <strong>",
"         are pregnant",
"        </strong>",
"        , avoid NSAIDs during the last 3 months of pregnancy. They are safe to use when breastfeeding.",
"       </li>",
"       <li>",
"        If you",
"        <strong>",
"         take any other prescription or non-prescription medicines",
"        </strong>",
"        , or you take any herbal medicines, ask your doctor or pharmacist if NSAIDs are safe for you. This is especially important if you take:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Blood thinners, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/2/33830?source=see_link\">",
"         warfarin",
"        </a>",
"        (brand name: Coumadin&reg;) or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/20/325?source=see_link\">",
"         heparin",
"        </a>",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/49/7958?source=see_link\">",
"         Phenytoin",
"        </a>",
"        (brand names: Dilantin&reg;, Phenytek&reg;), a medicine used to prevent seizures",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/62/38880?source=see_link\">",
"         Cyclosporine",
"        </a>",
"        , a medicine given to people who have had an organ transplant",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1726719\">",
"      <span class=\"h1\">",
"       What side effects can NSAIDs cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, NSAIDs cause no side effects. The side effects they do cause can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Stomach upset, ulcers, and bleeding",
"        </strong>",
"        &mdash;NSAIDs can cause stomach upset. If you take them regularly for a long time, NSAIDs can also cause ulcers or bleeding in the stomach or intestines.",
"       </li>",
"       <li>",
"        <strong>",
"         Liver damage",
"        </strong>",
"        &mdash; Long-term use of NSAIDs, especially at high doses, can harm the liver.",
"       </li>",
"       <li>",
"        <strong>",
"         Kidney damage",
"        </strong>",
"        &mdash; Using NSAIDs, even for a short time, can harm the kidneys. They are especially risky in people who already have kidney disease.",
"       </li>",
"       <li>",
"        <strong>",
"         Ringing in the ears",
"        </strong>",
"        &mdash; Ringing in the ears (tinnitus) is common in people who take high doses of",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        . It can also happen in people who take other NSAIDs. The ringing usually goes away when they take a lower dose.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1726726\">",
"      <span class=\"h1\">",
"       What happens if I take more than the recommended dose?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Taking more than the recommended dose of an NSAID might not cause serious problems. But it could make side effects much more likely without helping your symptoms very much. On the other hand, taking too much",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;) can be harmful or even cause death.",
"     </p>",
"     <p>",
"      Anybody who takes too much of any medicine at once should call a doctor or the Poison Control Hotline (1-800-222-1222). If the person is not breathing or is not conscious, call 9-1-1 for an ambulance.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1726768\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/15/40178?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16268 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40178=[""].join("\n");
var outline_f39_15_40178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1726698\">",
"      What are nonsteroidal antiinflammatory drugs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1726705\">",
"      Are all NSAIDs the same?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1726712\">",
"      Are NSAIDs safe for everyone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1726719\">",
"      What side effects can NSAIDs cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1726726\">",
"      What happens if I take more than the recommended dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1726768\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_15_40179="Patient information: Hemochromatosis (The Basics)";
var content_f39_15_40179=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15875\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/4/36930\">",
"         Patient information: Absent or irregular periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/52/22338\">",
"         Patient information: Blood donation (giving blood) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/54/3938\">",
"         Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/12/29891\">",
"         Patient information: Absent or irregular periods (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/12/26820\">",
"         Patient information: Blood donation and transfusion (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/22/9572\">",
"         Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/41/2709\">",
"         Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/54/15203\">",
"         Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hemochromatosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hemochromatosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16277076\">",
"      <span class=\"h1\">",
"       What is hemochromatosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hemochromatosis is a condition that can cause too much iron to build up in the body. This can lead to problems, such as liver damage, joint pain, and weakness.",
"     </p>",
"     <p>",
"      Hemochromatosis is caused by abnormal genes and can run in families. If your parent, brother, sister, or child has hemochromatosis, ask your doctor or nurse about getting tested for it.",
"     </p>",
"     <p>",
"      Most people find out they have hemochromatosis after a routine blood test or after being tested because a family member has it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277083\">",
"      <span class=\"h1\">",
"       What are the symptoms of hemochromatosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people find out they have hemochromatosis before they have any symptoms.",
"     </p>",
"     <p>",
"      If people do have symptoms before they are diagnosed, the symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An increase in the size of the liver (",
"        <a class=\"graphic graphic_figure graphicRef64960 \" href=\"mobipreview.htm?39/54/40804\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Feeling weak or tired",
"       </li>",
"       <li>",
"        Changes in the color of the skin that make it look darker",
"       </li>",
"       <li>",
"        Joint pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If hemochromatosis is not treated, it can lead to long-term problems that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        High sugar levels in the blood (diabetes mellitus)",
"       </li>",
"       <li>",
"        Trouble getting or keeping an erection (in men)",
"       </li>",
"       <li>",
"        Absent or irregular monthly periods (in women)",
"       </li>",
"       <li>",
"        Heart, thyroid, or liver problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277090\">",
"      <span class=\"h1\">",
"       Is there a test for hemochromatosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can do different blood tests to check the iron level in your blood. Based on the results, your doctor or nurse might order other tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277097\">",
"      <span class=\"h1\">",
"       How is hemochromatosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes, doctors do not treat hemochromatosis right away. People who do not have any symptoms are not usually treated at first. But their doctor will follow them closely by doing tests until treatment is needed.",
"     </p>",
"     <p>",
"      When treatment is needed, most people are treated by having some of their blood removed on a regular basis. Having blood taken from your body is also called &ldquo;phlebotomy.&rdquo; This treatment works because taking blood from a person&rsquo;s body can lower his or her iron level.",
"     </p>",
"     <p>",
"      If you are being treated for hemochromatosis, you will probably have blood taken once a week until your iron level is normal. This usually takes about 9 to 12 months. To track how well the treatment is working, your doctor or nurse will probably do a blood test to check your iron levels every 1 to 2 months.",
"     </p>",
"     <p>",
"      Once your iron level is normal, you will have treatment to keep your iron level from getting too high again. This involves having blood taken every 2 to 4 months. Most people need this treatment for the rest of their life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277104\">",
"      <span class=\"h1\">",
"       What other treatments might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might need other treatments if your hemochromatosis leads to long-term problems. For example, if you get diabetes, you might need to take diabetes medicines.",
"     </p>",
"     <p>",
"      If you have certain liver problems, you will need follow-up tests to check your liver for the rest of your life. That&rsquo;s because people with certain liver problems caused by hemochromatosis have a higher chance of getting liver cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277111\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to help keep my iron levels low?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You should avoid iron and vitamin C supplements. Supplements are pills, capsules, liquids, or tablets that have nutrients in them. Vitamin C supplements can cause the body to take in too much iron.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277118\">",
"      <span class=\"h1\">",
"       Can I drink alcohol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends. Ask your doctor or nurse if it is OK for you to drink alcohol. People who have hemochromatosis and certain liver problems should not drink alcohol.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277125\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have hemochromatosis and want to get pregnant, talk with your doctor or nurse. He or she might suggest that your partner be tested for hemochromatosis. That way, you will know if your child has a higher chance of getting it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16277132\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/52/22338?source=see_link\">",
"       Patient information: Blood donation (giving blood) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/4/36930?source=see_link\">",
"       Patient information: Absent or irregular periods (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/54/3938?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/41/2709?source=see_link\">",
"       Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=see_link\">",
"       Patient information: Blood donation and transfusion (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=see_link\">",
"       Patient information: Absent or irregular periods (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15203?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/15/40179?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15875 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40179=[""].join("\n");
var outline_f39_15_40179=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277076\">",
"      What is hemochromatosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277083\">",
"      What are the symptoms of hemochromatosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277090\">",
"      Is there a test for hemochromatosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277097\">",
"      How is hemochromatosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277104\">",
"      What other treatments might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277111\">",
"      Is there anything I can do on my own to help keep my iron levels low?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277118\">",
"      Can I drink alcohol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277125\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16277132\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15875\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/52/22338?source=related_link\">",
"      Patient information: Blood donation (giving blood) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/41/2709?source=related_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_15_40180="Brompheniramine: Patient drug information";
var content_f39_15_40180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Brompheniramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/29/39381?source=see_link\">",
"     see \"Brompheniramine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3286540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bromax [DSC];",
"     </li>",
"     <li>",
"      J-Tan PD [OTC];",
"     </li>",
"     <li>",
"      LoHist-12 [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to brompheniramine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, glaucoma, ulcer disease, or trouble passing urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11930 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40180=[""].join("\n");
var outline_f39_15_40180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286540\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019669\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019671\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019670\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019675\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019676\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019678\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019673\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019674\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019679\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019680\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/29/39381?source=related_link\">",
"      Brompheniramine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_15_40181="Pizotifen: Drug information";
var content_f39_15_40181=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pizotifen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/28/4549?source=see_link\">",
"    see \"Pizotifen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sandomigran DS&reg;;",
"     </li>",
"     <li>",
"      Sandomigran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Serotonin and Histamine Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Migraine prophylaxis:",
"     </b>",
"     Oral: Initial: 0.5 mg at bedtime; may increase dose gradually to 1.5 mg daily administered as single dose or in 3 divided doses; average maintenance dose: 1.5 mg daily; usual dosage range: 1-6 mg daily. Doses &gt;3 mg should be administered in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapeutic response may require several weeks of therapy. Drug holidays are recommended periodically to assess the need for ongoing therapy. Do not discontinue abruptly (reduce gradually over 2-week period).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F210816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Migraine prophylaxis:",
"     </b>",
"     Adolescents &ge;12 years: Oral: Initial: 0.5 mg at bedtime; may increase dose gradually up to maximum of 1.5 mg daily. Doses &gt;1 mg should be administered in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapeutic response may require several weeks of therapy. Drug holidays are recommended periodically to assess the need for ongoing therapy. Do not discontinue abruptly (reduce gradually over 2-week period).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly (&gt;65 years): Use with caution. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15872022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustment provided in manufacturer&rsquo;s labeling; however, the manufacturer suggests that dosage adjustments may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15872023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustment provided in manufacturer&rsquo;s labeling; however, the manufacturer suggests that dosage adjustments may be necessary. Pizotifen undergoes hepatic metabolism mainly via glucuronidation.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sandomigran&reg;: 0.5 mg [pizotifen malate 0.73 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, double strength:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sandomigran&reg; DS: 1 mg [pizotifen malate 1.46 mg]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Migraine prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;10%: Gastrointestinal: Appetite increased, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to &lt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness (including fatigue, somnolence)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation/aggression (children), amenorrhea, anorexia, anxiety, arthralgia, breast enlargement, breast pain, constipation, depression, diplopia, facial edema, fulminant hepatitis, hallucination, hepatitis, hepatic enzymes increased, hypersensitivity reactions, insomnia,  intraocular pressure increased, jaundice, loss of consciousness, muscle cramps, myalgia, nonpuerperal lactation, paresthesia, pupil dilation, rash, sedation, seizure, sleep disorder, tremor, urticaria, weight loss (rapid), withdrawal (following abrupt cessation of therapy)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F210791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pizotifen or any component of the formulation; concurrent use of MAO inhibitors; gastric outlet obstruction (pyloroduodenal obstruction, stenosing pyloric ulcer); use in children &lt;12 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F210777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Although anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention) are limited; use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, narrow-angle glaucoma, or other vision problems. Use with caution in patients intolerant to anticholinergic agents, including tricyclic antidepressants, phenothiazines, or cyproheptadine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Gradual titration of dose may help minimize sedative effects (eg, drowsiness).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Hepatotoxic effects may occur with prolonged used; periodic evaluation of liver function is recommended during therapy. Discontinue use for signs/symptoms of hepatic dysfunction and do not resume therapy until etiology of hepatic dysfunction is identified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: Use has been associated with increased intraocular pressure, diplopia, and pupil dilation; limited number of patients experienced lens opacities but effect was not considered drug-related. Instruct patients to report visual disturbances during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain/loss: Increased appetite and weight gain are common adverse effects; patients may experience rapid weight loss upon discontinuation.  Use with caution in obese or other patients who may be vulnerable to these effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use with caution in patients with epilepsy; seizures have been reported very rarely with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: May contain lactose; avoid use in patients with galactose or fructose intolerance, lactase deficiency, sucrose-isomaltase insufficiency, or glucose-galactose malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt discontinuation: Avoid abrupt discontinuation which may cause acute withdrawal reactions (eg, depression, dizziness, anxiety, loss of consciousness, anorexia and rapid weight loss); taper dosage over 2 weeks prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not for use in acute treatment of migraine attacks or of tension headaches. Not considered first-line agent for migraine prophylaxis but may be considered when other therapies have failed (Pringsheim, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Response to therapy: Therapeutic response may require several weeks of therapy. Some patients may experience a decrease in therapeutic response over time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: May develop in some patients; effect may be overcome by dose increases (not to exceed maximum dosage). Consider drug-free period after several months of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F210799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F210793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. If possible, drug therapy for migraine prophylaxis should be avoided during pregnancy. If therapy is needed, other agents are preferred (Pringsheim, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15868078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15868079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The concentration of pizotifen measured in the milk of nursing mothers is unlikely to affect a nursing infant; however, the manufacturer does not recommend use in nursing mothers. If possible, drug therapy for migraine prophylaxis should be avoided in nursing women. If therapy is needed, other agents are preferred (Pringsheim, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F210784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic function tests (prolonged use); weight gain; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F210794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acugrain (MY);",
"     </li>",
"     <li>",
"      Anorsia (TH);",
"     </li>",
"     <li>",
"      Lematite (PK);",
"     </li>",
"     <li>",
"      Litec (PH);",
"     </li>",
"     <li>",
"      Lysagor (ID);",
"     </li>",
"     <li>",
"      Mor-Vita (PH);",
"     </li>",
"     <li>",
"      Mosegor (CH, DE, ES, GR, LU, PH, PK, PT);",
"     </li>",
"     <li>",
"      Pizomed (TH);",
"     </li>",
"     <li>",
"      Polomigran (PL);",
"     </li>",
"     <li>",
"      Sandomigran (AR, AT, AU, BE, BR, CZ, DE, ES, FR, GB, HK, HU, IE, IL, IT, LU, MY, NL, NZ, VE);",
"     </li>",
"     <li>",
"      Sandomigrin (DK, NO, SE, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F210776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pizotifen is a strong serotonin antagonist and has weak antihistamine, anticholinergic and antikinin effects; also has appetite-stimulating and sedative properties. The mechanism of action in migraine prophylaxis has not been fully elucidated; may alter pain thresholds by inhibiting the permeability increasing effect of serotonin and histamine to control movement of plasma kinin across cranial vessel membranes.  Inhibits serotonin reuptake by platelets, affecting tonicity and reducing passive distension of extracranial arteries.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F210790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: May require several weeks of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Parent drug: 833 L; N-glucuronide metabolite: 70 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (mainly by glucuronidation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 78%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~23 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~33% of dose); urine (55% as metabolites, &lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Elouni B, Ben Salem C, Zamy M, et al, &ldquo;Fulminant Hepatitis Possibly Related to Pizotifen Therapy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(7-8):1348-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40181/abstract-text/20571104/pubmed\" id=\"20571104\" target=\"_blank\">",
"        20571104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pringsheim T, Davenport W, Mackie G, et al, &ldquo;Canadian Headache Society Guideline for Migraine Prophylaxis,&rdquo;",
"      <i>",
"       Can J Neurol Sci",
"      </i>",
"      , 2012, 39(2 Suppl 2):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40181/abstract-text/22683887/pubmed\" id=\"22683887\" target=\"_blank\">",
"        22683887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10091 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-AA34A315B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40181=[""].join("\n");
var outline_f39_15_40181=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210801\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210831\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210803\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210816\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210804\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15872022\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15872023\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076329\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234284\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210788\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210829\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210791\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210777\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299887\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210781\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210799\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210793\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15868078\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15868079\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210784\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210794\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210776\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210790\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10091\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10091|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/28/4549?source=related_link\">",
"      Pizotifen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_15_40182="Bumetanide: Pediatric drug information";
var content_f39_15_40182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bumetanide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"    see \"Bumetanide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/28/29125?source=see_link\">",
"    see \"Bumetanide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Burinex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Loop",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral, I.M., I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Doses in the higher end of the range may be required for patients with heart failure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preterm neonates: 0.01-0.05 mg/kg/dose every 24-48 hours (Lopez-Samplas, 1997; Shankaran, 1995); a retrospective trial reported a mean dose of 0.03 mg/kg/dose every 12-24 hours for oliguric acute renal failure (n=35; PMA: 24-36 weeks) (maximum reported dose: 0.06 mg/kg/dose) (Oliveros, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Term neonates: 0.01-0.05 mg/kg/dose every 12-24 hours (Sullivan, 1996; Ward, 1977)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"      see \"Bumetanide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: Oral, I.M., I.V.: 0.015-0.1 mg/kg/dose every 6-24 hours (maximum dose: 10 mg/day); a prospective, open-label dose-range study in infants (mean age: 2 months; range: 0-6 months) reported a maximal diuretic response at doses 0.035-0.04 mg/kg/dose every 6-8 hours, and no additional clinical benefit (ie, urine output) at doses &gt;0.05 mg/kg/dose (Sullivan, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edema:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 0.5-2 mg/dose 1-2 times/day; if diuretic response to initial dose is not adequate, may repeat in 4-5 hours for up to 2 doses (maximum daily dose: 10 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 0.5-1 mg/dose; may repeat in 2-3 hours for up to 2 doses if needed (maximum daily dose: 10 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypertension: Oral: 0.5 mg daily (maximum daily dose: 5 mg/",
"     <b>",
"      day",
"     </b>",
"     ); usual dosage range (JNC 7): 0.5-2 mg divided twice daily (Chobanian, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.25 mg/mL (2 mL, 4 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food to decrease GI irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Administer without additional dilution by direct I.V. injection over 1-2 minutes; for intermittent I.V. infusion, dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, or NS and infuse over 5 minutes (Rudy, 1991); pH: 6.8-7.8",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F142883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, bivalirudin, caspofungin, cefepime, cisatracurium, cladribine, dexmedetomidine, diltiazem, docetaxel, doripenem, etoposide phosphate, filgrastim, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), lorazepam, melphalan, meperidine, micafungin, milrinone, morphine, oxaliplatin, pemetrexed, piperacillin/tazobactam, propofol, remifentanil, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fenoldopam, midazolam, nesiritide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light; may discolor when exposed to light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of edema secondary to heart failure or hepatic or renal disease, including nephrotic syndrome (FDA approved in adults); has also been used to reverse oliguria in preterm neonates and for the treatment of hypertension alone or in combination with other antihypertensive agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F142885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bumetanide may be confused with Buminate&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bumex&reg; may be confused with Brevibloc&reg;, Buprenex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bumex [U.S.] may be confused with Permax brand name for pergolide [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F142882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Bicarbonate altered, calcium altered, CO",
"     <sub>",
"      2",
"     </sub>",
"     content altered, hyperglycemia, hyperuricemia, hypochloremia, hypokalemia, hyponatremia, phosphorus altered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: LDH altered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, alkaline phosphatase altered, arthritic pain, asterixis, bilirubin altered, chest pain, cholesterol altered, creatinine clearance altered, dehydration, diaphoresis, diarrhea, ear discomfort, ECG changes, encephalopathy (in patients with pre-existing liver disease), erectile dysfunction, fatigue, headache, hearing impaired, hemoglobin/hematocrit altered, hives, hypernatremia, hyperventilation, hypotension, musculoskeletal pain, nausea, nipple tenderness, orthostatic hypotension, ototoxicity, premature ejaculation, prothrombin time altered, pruritus, rash, renal failure, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, transaminase altered, upset stomach, urine glucose increased, urine protein increased, vertigo, vomiting, WBC altered, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bumetanide or any component; anuria or increasing azotemia; hepatic coma; severe electrolyte depletion (until condition is improved or corrected)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cirrhosis; avoid sudden changes in fluid and electrolyte balance and acid/base status which may lead to hepatic encephalopathy. Administration with an aldosterone antagonist or potassium-sparing diuretic may provide additional diuretic efficacy and maintain normokalemia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid); the manufacturer&rsquo;s labeling states that bumetanide may be used in patients allergic to furosemide. Use in patients with sulfonylurea allergy is not specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Bumetanide increases urinary excretion of calcium and magnesium and may lead to hypocalcemia and hypomagnesemia; asymptomatic hyperuricemia has also been reported. Glucose alterations may occur with bumetanide use; serum glucose should be monitored during therapy especially in patients with or suspected to have diabetes.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Loop diuretics are potent diuretics; excess amounts can lead to profound diuresis with fluid and electrolyte loss",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; close medical supervision and dose evaluation is required. Potassium supplementation and/or use of potassium-sparing diuretics may be necessary to prevent hypokalemia. Monitor fluid status and renal function in an attempt to prevent oliguria, azotemia, and reversible increases in BUN and creatinine; close medical supervision of aggressive diuresis required. Coadministration of antihypertensives may increase the risk of hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ototoxicity has been demonstrated following oral administration of torsemide and following rapid I.V. administration of other loop diuretics. Other possible risk factors may include use in renal impairment, excessive doses, and concurrent use of other ototoxins (eg, aminoglycosides).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Although rare, thrombocytopenia has been reported; routinely monitor for possible occurrence.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Parenteral formulation contains  benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of  parenteral formulations containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"     <i>",
"      In vitro",
"     </i>",
"     studies using pooled sera from critically ill neonates have shown bumetanide to be a potent displacer of bilirubin; use with caution in neonates at risk for kernicterus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Loop Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. This by increasing the risk of hypokalemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Loop Diuretics may diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May diminish the therapeutic effect of Loop Diuretics. Methotrexate may increase the serum concentration of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE.  Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Loop Diuretics may enhance the hypokalemic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10169661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, serum electrolytes, renal function, urine output",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits reabsorption of sodium and chloride in the ascending loop of Henle and proximal renal tubule, interfering with the chloride-binding cotransport system, thus causing increased excretion of water, sodium, chloride, magnesium, calcium, and phosphate",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M.: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within a few minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Neonates and infants: 0.26-0.39 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partial metabolism occurs in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 59% to 89% (median: 80%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature and full term neonates: 6 hours (range up to 15 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;2 months: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 2-6 months: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Unchanged drug excreted in urine (45%); biliary/fecal (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preterm and full term neonates: 0.2-1.1 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;2 months: 2.17 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 2-6 months: 3.8 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 2.9 &plusmn; 0.2 mL/minute/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/28/29125?source=see_link\">",
"      see \"Bumetanide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1057008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with impaired hepatic function must be monitored carefully, often requiring reduced doses; larger doses may be necessary in patients with impaired renal function to obtain the same therapeutic response; 1 mg bumetanide approximately equivalent in potency to 40 mg furosemide",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brater DC, \"Clinical Pharmacology of Loop Diuretics,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 41 Suppl 3:14-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/1712712/pubmed\" id=\"1712712\" target=\"_blank\">",
"        1712712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/12748199 /pubmed\" id=\"12748199 \" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cook JA, Smith DE, Cornish LA, et al, \"Kinetics, Dynamics, and Bioavailability of Bumetanide in Healthy Subjects and Patients With Congestive Heart Failure,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1988, 44(5):487-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/3180632/pubmed\" id=\"3180632\" target=\"_blank\">",
"        3180632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Samblas AM, Adams JA, Goldberg RN, et al, \"The Pharmacokinetics of Bumetanide in the Newborn Infant,\"",
"      <i>",
"       Biol Neonate",
"      </i>",
"      , 1997, 72(5):265-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/9395836/pubmed\" id=\"9395836\" target=\"_blank\">",
"        9395836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oliveros M, Pham JT, John E, et al, \"The Use of Bumetanide for Oliguric Acute Renal Failure in Preterm Infants,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2011, 12(2):210-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/20625335/pubmed\" id=\"20625335\" target=\"_blank\">",
"        20625335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudy DW, Voelker JR, Greene PK, et al, \"Loop Diuretics for Chronic Renal Insufficiency: A Continuous Infusion Is More Efficacious Than Bolus Therapy,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1991, 115(5):360-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/1863026/pubmed\" id=\"1863026\" target=\"_blank\">",
"        1863026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shankaran S, Liang KC, Ilagan N, et al, \"Mineral Excretion Following Furosemide Compared With Bumetanide Therapy in Premature Infants,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 1995, 9(2):159-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/7794709/pubmed\" id=\"7794709\" target=\"_blank\">",
"        7794709",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sullivan JE, Witte MK, Yamashita TS, et al, \"Analysis of the Variability in the Pharmacokinetics and Pharmacodynamics of Bumetanide in Critically Ill Infants,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(4):414-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/8873689/pubmed\" id=\"8873689\" target=\"_blank\">",
"        8873689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sullivan JE, Witte MK, Yamashita TS, et al, \"Dose-Ranging Evaluation of Bumetanide Pharmacodynamics in Critically Ill Infants,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(4):424-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/8873690/pubmed\" id=\"8873690\" target=\"_blank\">",
"        8873690",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ward OC and Lam LK, \"Bumetanide in Heart Failure in Infancy,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1977, 52(11):877-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/413494/pubmed\" id=\"413494\" target=\"_blank\">",
"        413494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells TG, &ldquo;The Pharmacology and Therapeutics of Diuretics in the Pediatric Patient,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1990, 37(2):463-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/15/40182/abstract-text/2184406 /pubmed\" id=\"2184406 \" target=\"_blank\">",
"        2184406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13097 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40182=[""].join("\n");
var outline_f39_15_40182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708637\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142835\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056999\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442104\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056992\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142810\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142795\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057003\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142883\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056995\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057002\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142885\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142882\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057007\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056991\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056990\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298906\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142804\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142806\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10169661\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056998\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056989\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057005\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057006\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056997\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057008\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13097\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13097|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=related_link\">",
"      Bumetanide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/28/29125?source=related_link\">",
"      Bumetanide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_15_40183="Scalp psoriasis";
var content_f39_15_40183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Psoriasis vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Well-demarcated, erythematous, scaly plaques are present on the neck and scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40183=[""].join("\n");
var outline_f39_15_40183=null;
var title_f39_15_40184="Diseases associated with atherosclerosis in childhood";
var content_f39_15_40184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"20\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diseases associated with atherosclerosis in childhood",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/15/40184/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/15/40184/contributors\">",
"     Sarah D de Ferranti, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/15/40184/contributors\">",
"     Jane W Newburger, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/15/40184/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/15/40184/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/15/40184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/15/40184/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/15/40184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiovascular disease (CVD) generally manifests in adulthood, the process of atherosclerosis can begin in early childhood. For most children, atherosclerotic vascular changes are minor and can be minimized or even prevented with adherence to a healthy lifestyle. However, in some children, the process is accelerated because of the presence of identifiable risk factors (eg, obesity and hypertension)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specific diseases that are associated with premature CVD (eg, diabetes and Kawasaki disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatric diseases that are associated with an increased risk of accelerated atherosclerosis and CVD will be discussed here. Identification and management of children at risk for atherosclerosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=see_link\">",
"     \"Risk factors and development of atherosclerosis in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION BASED ON SPECIFIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific disease states are associated with early cardiovascular disease (CVD) and accelerated atherosclerosis. In a scientific statement from the American Heart Association (AHA), a panel of experts reviewed the literature on premature cardiovascular disease in children and established a disease risk stratification schema for coronary artery disease (CAD), which was revised into a two-tier schema by the National Heart, Lung, and Blood Institute (NHLBI) panel in 2011 (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This schema separated diseases into high and moderate risk categories for CVD as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &ndash; Pathologic or clinical evidence of CAD before 30 years of age. Diseases in this category include types 1 and 2 diabetes mellitus, chronic kidney disease, heart transplant recipients, and Kawasaki disease with current coronary aneurysms.",
"     </li>",
"     <li>",
"      Moderate risk &ndash; Pathophysiologic evidence for accelerated atherosclerosis before 30 years of life. Diseases in this category include Kawasaki disease with regressed coronary aneurysms, chronic inflammatory disease, HIV infection, and nephrotic syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to adults, in whom multiple risk factors are considered in evaluation of risk for CVD, children who are initially placed in the moderate can move to the high risk tier if they have additional risk factors (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal fasting lipid profile",
"     </li>",
"     <li>",
"      Family history of early coronary artery disease",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Increased body mass index",
"     </li>",
"     <li>",
"      Fasting blood glucose greater than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Smoke exposure",
"     </li>",
"     <li>",
"      Sedentary lifestyle",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FAMILIAL HYPERCHOLESTEROLEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial hypercholesterolemia (FH) is a monogenic, autosomal disorder caused by defects in the gene that encodes for the apolipoprotein",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor. The associated impairment in function of these receptors results in reduced clearance of LDL-C particles from the circulation and an elevation in serum LDL-C.",
"   </p>",
"   <p>",
"    In patients who have homozygous FH, cardiovascular disease (CVD) can present within the first two decades of life. Heterozygotes, although less severely affected, are also at risk for premature CVD, occurring before age 55 years in men and 65 years in women.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of familial hypercholesterolemia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial hypercholesterolemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIABETES MELLITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance, hyperinsulinemia, and elevated blood glucose are associated with atherosclerotic cardiovascular disease (CVD). In addition, children with diabetes compared to those without diabetes are at increased risk for other atherogenic risk factors, such as hypertension and dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H4873275#H4873275\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adolescents with type 1 disease, accelerated atherosclerotic changes have been described at autopsy and in studies that demonstrate increased carotid intima-media thickness. Other noninvasive tests of vascular function, including arterial stiffness and endothelial function, are abnormal in patients with type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/4\">",
"     4",
"    </a>",
"    ]. Improvements in LDL levels were reported with a 12 week course of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21432?source=see_link\">",
"     atorvastatin",
"    </a>",
"    treatment even though LDL levels were not excessively elevated (mean LDL 87",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    supporting the hypothesis that an adverse impact of type 1 diabetes mellitus on vascular health is independent of LDL elevations in the pediatric population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/5\">",
"     5",
"    </a>",
"    ]. There have also been reports of myocardial infarctions in young adults with type 1 diabetes mellitus.",
"   </p>",
"   <p>",
"    In adolescents with type 2 diabetes mellitus (characterized by variable degrees of insulin deficiency and resistance), cardiovascular abnormalities, such as increased left ventricular wall thickness and increased arterial stiffness, have been reported. Children with type 2 disease are often obese and are at increased risk of developing metabolic syndrome (also referred to as syndrome X or insulin resistance syndrome), a condition of multiple CVD risk factors (ie, dyslipidemia, hypertension, type 2 diabetes mellitus, and obesity). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of types 1 and 2 diabetes mellitus, including screening and prevention of CVD, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H30#H30\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Cardiovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=see_link&amp;anchor=H11#H11\">",
"     \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\", section on 'Vascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with chronic and end-stage kidney disease (ESRD) are at increased risk for developing cardiovascular disease (CVD). A quarter of deaths in children with ESRD are due to CVD. Accelerated atherosclerosis has been demonstrated in iliac artery samples at the time of renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/6\">",
"     6",
"    </a>",
"    ] or at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with ESRD are at risk for CVD risk factors, including hypertension and dyslipidemia. They have cardiovascular abnormalities (eg, left ventricular hypertrophy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/8\">",
"     8",
"    </a>",
"    ] and evidence of early atherosclerosis, including coronary artery calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/7\">",
"     7",
"    </a>",
"    ], abnormal flow mediated dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/9\">",
"     9",
"    </a>",
"    ], increased carotis intimal-medial thickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/10\">",
"     10",
"    </a>",
"    ], and increased aortic stiffness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. These abnormalities seem to be, in part, related to the degree of uremia. Furthermore, lipids may have toxic effects on kidney function; a trial is comparing the effect of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21432?source=see_link\">",
"     atorvastatin",
"    </a>",
"    therapy to placebo on renal function is currently addressing this question [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Dyslipidemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link\">",
"     \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some medications used to prevent renal transplant rejection are associated with CVD risk factors. These include the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      is associated with hypertension",
"     </li>",
"     <li>",
"      Rapamycin is associated with dyslipidemia",
"     </li>",
"     <li>",
"      Corticosteroids are associated with hypertriglyceridemia, hypertension, and diabetes (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"       \"Lipid abnormalities after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment is directed at reduction of other CVD risk factors such as hypertension and dyslipidemia. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for controlling the epidemic of CV disease in CRD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/KDOQI/guidelines_commentaries.cfm\">",
"     National Kidney Foundation's web site",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CARDIAC TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children who undergo cardiac transplantation, transplant vasculopathy resulting in coronary artery stenosis is a significant long-term complication and cause of death that can occur even in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/14\">",
"     14",
"    </a>",
"    ]. A multicenter autopsy study demonstrated severe coronary stenosis in 28 of 36 children deceased after cardiac transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/14\">",
"     14",
"    </a>",
"    ]. About three-quarters of children with cardiac transplantation have evidence of coronary artery abnormalities detected by angiography and intracoronary ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac transplant vasculopathy appears to be multifactorial in origin with both immunologic and nonimmunologic factors being implicated. Among the factors associated with vasculopathy are cellular and vascular rejection, anti-HLA antibody production, and cytomegalovirus infection. Patients with cardiac transplants are likely to have other cardiovascular disease (CVD) risk factors, such as dyslipidemia, hypertension, overweight, diabetes, and deconditioning. Similar to children who undergo renal transplantation, these additional risk factors may be associated with medications used to prevent rejection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/25/44441?source=see_link\">",
"     \"Pathogenesis of and risk factors for cardiac allograft vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Chronic kidney disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The management of patients with cardiac transplantation to prevent and treat cardiac transplant vasculopathy, and to screen and treat dyslipidemia, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/25000?source=see_link\">",
"     \"Lipid abnormalities after cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     KAWASAKI DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease (KD, also called mucocutaneous lymph node syndrome) is one of the most common vasculitides of childhood. Children with KD can develop coronary artery aneurysms, which can lead to myocardial ischemia or infarction (",
"    <a class=\"graphic graphic_movie graphicRef65317 \" href=\"mobipreview.htm?35/29/36318\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef53864 \" href=\"mobipreview.htm?18/43/19134\">",
"     movie 2",
"    </a>",
"    ). In developed countries, KD has surpassed rheumatic fever as the leading cause of acquired cardiovascular disease (CVD) in childhood.",
"   </p>",
"   <p>",
"    In untreated patients, the incidence of coronary artery aneurysms is about 20 to 25 percent, with a mortality rate of approximately 2 percent. The incidence of aneurysms is reduced to less than 5 percent when patients receive intravenous immunoglobulin during the acute phase of their illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subsequent risk of CVD in children with Kawasaki disease is dependent upon the presence and natural course of coronary artery aneurysms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &ndash; In half of the children with coronary artery aneurysms, the aneurysm will persist and occasionally will progress to stenosis at the proximal or distal ends of the original aneurysms. Patients with giant-sized defects (greater than 8 mm in diameter) are at the highest risk for persistent aneurysms, late coronary ischemia, and myocardial infarction. In addition, children with coronary aneurysms have greater carotid intima-medial thickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/17\">",
"       17",
"      </a>",
"      ] and reduced coronary artery vasoreactivity compared with controls with history of KD, but no persistent aneurysms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Moderate risk &ndash; In half of the children with coronary artery aneurysms, the aneurysm will regress to normal size, likely due to the process of myointimal proliferation. Patients with regressed aneurysms, as well as those with persistent aneurysms, have findings of accelerated atherosclerosis, such as abnormal coronary histopathology, diminished vascular reactivity, increased arterial stiffness, and diminished coronary flow reserve.",
"     </li>",
"     <li>",
"      It is uncertain whether patients without coronary artery abnormalities in the initial phase of the disease are at increased risk for CVD compared to the general pediatric population. A 10- to 21-year follow-up study of 594 patients with Kawasaki disease demonstrated few cardiovascular events in patients without coronary artery aneurysms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/19\">",
"       19",
"      </a>",
"      ]. In recent follow-up of Japanese children who had KD between July 1982 and December 1992, the standardized mortality ratio for patients without cardiac sequelae was not higher than that of the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/20\">",
"       20",
"      </a>",
"      ]. Two studies in North America have shown no changes in vascular function in KD patients who never had coronary aneurysms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have reported changes in vascular function consistent with accelerated atherosclerosis, including increased arterial stiffness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], decreased brachial artery reactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/25\">",
"     25",
"    </a>",
"    ], and decreased myocardial blood flow and coronary flow reserve with adenosine in KD patients who had never had coronary abnormalities. Children with Kawasaki disease are more likely to have low HDL than the general pediatric population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal follow-up for adults with a history of KD without coronary abnormalities is a topic of great controversy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    All patients with a history of KD should be screened for other CVD risk factors (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ). Those with additional risk factors and patients with aneurysms, especially if they are persistent, are at a higher risk for CVD. Therapeutic interventions are initiated based upon the CVD risk for the individual patient and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link&amp;anchor=H242698963#H242698963\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHRONIC INFLAMMATORY DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well established that the prevalence of cardiovascular disease (CVD) is increased in adults with chronic inflammatory illnesses, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Increasing evidence suggests that children and adolescents affected by these disorders often have increased CVD risk factors, with nearly three-quarters reported to have a lipid disorder accelerated atherosclerosis, and a higher risk of premature cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/29\">",
"     29",
"    </a>",
"    ]. They can also have accelerated atherosclerosis and a higher risk of premature cardiovascular events. Children and adolescents with SLE have increased carotid intimal-medial thickness compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/30\">",
"     30",
"    </a>",
"    ], and there are case reports of myocardial infarctions and abnormalities in coronary perfusion detected by myocardial perfusion scanning in pediatric patients with SLE. In addition, children with chronic inflammatory disease have an increased likelihood of having other CVD risk factors, such as dyslipidemia, hypertension, inactivity, and overweight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/12/31943?source=see_link\">",
"     \"Cardiac abnormalities in children and adolescents with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CANCER SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the long-term survival rate improves for pediatric cancer, it has become increasingly apparent that these patients are at-risk for significant premature cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/31\">",
"     31",
"    </a>",
"    ]. The combination of damaged myocardium from chemotherapeutic agents and acquired atherosclerotic disease has resulted in an eightfold increase in deaths due to cardiac disease among survivors of childhood cancer beyond five years of diagnosis compared to the general population, and a five- to sixfold increase compared to siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/31\">",
"     31",
"    </a>",
"    ]. In adults, mediastinal radiation therapy is also associated with premature atherosclerosis with the highest relative risk estimates in patients treated as children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survivors of childhood cancer are more likely to have other cardiovascular disease (CVD) risk factors including obesity, insulin resistance, dyslipidemia, growth hormone deficiency, and deconditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/33-38\">",
"     33-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 201 long-term survivors, the cancer survivor group compared with their healthy siblings had an increased risk of CVD due to the combination of reduced left ventricular mass due to toxicity from chemotherapy and increased prevalence of CVD risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 319 childhood cancer survivors in remission &ge;5 years (mean age 14.5 years), the cancer survivor group compared with their siblings were more likely to have CVD risk factors including dyslipidemia, increased insulin resistance, and altered body composition with greater adiposity and less lean body mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Children's Oncology Group has developed guidelines for monitoring of CVD risk in childhood cancer survivors after completion of their oncologic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/32\">",
"     32",
"    </a>",
"    ]. These guidelines are based upon studies of childhood cancer survivors that have established the association of cancer survival with premature CVD. However, these guidelines have not been validated in clinical trials, because the relatively small size of the survivor population and the prevalence and latency of cardiovascular sequelae precludes the ability to evaluate the impact of screening upon CVD mortality and morbidity associated with childhood cancer therapy. The guidelines include the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of an individual's risk for cardiovascular disease based upon their treatment regimen regarding chemotherapeutic agents and their cumulative dose, and the use and dose of mediastinal radiation therapy",
"     </li>",
"     <li>",
"      At each clinical encounter, a complete history and physical including screening for cardiac symptoms (eg, dyspnea, chest pain, palpitations, and effort intolerance) and transient neurologic symptoms (eg, loss of sensation, paresthesias, weakness, or visual or auditory changes), which may represent cardiac dysfunction.",
"     </li>",
"     <li>",
"      Screen for other cardiovascular risk factors; in patients who received mediastinal radiation, the guidelines suggest obtaining a fasting glucose and lipid profile every three to five years because of their increased risk for premature CVD.",
"     </li>",
"     <li>",
"      In patients who were exposed to cardiotoxic drugs or mediastinal radiation therapy, baseline echocardiogram and electrocardiogram should be obtained for comparison with subsequent studies, which would be indicated if cardiac symptoms develop",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONGENITAL HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital heart disease occurs in almost 1 in every 100 live births. Because of improved palliative and corrective surgery, many more children are surviving to adulthood. As a result, there is increasing evidence that some congenital heart defects are associated with an increased risk for premature atherosclerosis and cardiovascular disease (CVD). Recent studies suggest children with congenital heart disease are not immune to the effects of the obesity epidemic. Observational data support a prevalence of overweight and obesity similar to that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/39\">",
"     39",
"    </a>",
"    ]. Risk of atherosclerotic CVD is likely to be greatest in those with coronary artery abnormalities or left-sided obstructive lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary artery abnormalities &ndash; In patients with coronary artery anomalies, premature atherosclerosis of the coronary artery has been demonstrated in autopsies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/24\">",
"       24",
"      </a>",
"      ] and detected by coronary artery angiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/40\">",
"       40",
"      </a>",
"      ]. In addition, surgical manipulation of the coronary arteries, especially associated with the arterial switch operation for transposition of the great arteries (TGA), is associated with increased risk for coronary artery stenosis, premature atherosclerosis, and coronary artery dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. Rates of overweight and obesity were measured in 106 children born with TGA who underwent arterial switch or Ross operations; overweight and obesity were seen in 31 percent of patients at a rate comparable to US children overall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/44\">",
"       44",
"      </a>",
"      ]. Parents reported that early feeding and physical activity restriction practices in obese and overweight TGA patients were not greater than in the normal weight children with TGA. Of concern, left ventricular mass was higher, indicating that the extra weight has a physiologic consequence that is particularly concerning for a child whose heart may already be vulnerable.",
"     </li>",
"     <li>",
"      Left-sided obstructive lesions &ndash; Cardiac lesions that obstruct the left ventricle or aorta, such as aortic stenosis, are associated with an increased risk of CVD in adulthood. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=see_link&amp;anchor=H11#H11\">",
"       \"Medical management of asymptomatic aortic stenosis in adults\", section on 'Coronary artery disease'",
"      </a>",
"      .) In children with coarctation of the aorta, the aorta is less compliant and reactive, and the carotid and femoral intima media thickness is increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/45\">",
"       45",
"      </a>",
"      ]. Approximately 50 percent of individuals with coarctation have hypertension, even years after apparently successful repair. Children with left-sided lesions often have left ventricular hypertrophy, a CVD risk factor in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H283187#H283187\">",
"       \"Overview of the possible risk factors for cardiovascular disease\", section on 'Left ventricular hypertrophy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of these children includes treatment of their underlying disease and any associated comorbid conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the American Heart Association (AHA) statement, recommendations for initiating treatment for comorbid conditions are made based upon the assessed risk of the individual patient. For the child in the high-risk tier, interventions for elevated blood pressures (BP), LDL-C, and overweight are suggested at lower cut points than those in the moderate-risk tier. Cut points are less stringent for those who are only at-risk. The goal of therapy should be to reduce the risk factor towards normal, with the threshold for treatment varying by risk tier listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40184/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overweight: BMI and BMI percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/14/36070?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/60/35782?source=see_link\">",
"       calculator 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High risk: BMI &gt;85th percentile for age and gender",
"     </li>",
"     <li>",
"      Moderate risk: BMI &gt;90th percentile for age and gender",
"     </li>",
"     <li>",
"      At-risk: BMI &gt;95th percentile for age and gender",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High risk: BP &gt;90th percentile for age and gender",
"     </li>",
"     <li>",
"      Moderate risk: BP &gt;95th percentile for age and gender",
"     </li>",
"     <li>",
"      At-risk: BMI &gt;95th percentile for age and gender + 5 mm Hg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"     calculator 3",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"     calculator 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LDL-C",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High risk: LDL-C &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Moderate risk: LDL-C &gt;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.35",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      At-risk: LDL-C &gt;160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fasting glucose &ndash; For any child with one of the above eight diseases, regardless of risk classification, if the fasting glucose is greater than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or the hemoglobin A1C is greater than 7 percent, an intervention should be prescribed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interventions for the comorbidities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/35/4660?source=see_link\">",
"       \"Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific pediatric diseases are associated with an increased risk of accelerated atherosclerosis and cardiovascular disease (CVD). The American Heart Association (AHA) has identified the following conditions that are associated with CVD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Familial hypercholesterolemia",
"     </li>",
"     <li>",
"      Types 1 and 2 diabetes mellitus",
"     </li>",
"     <li>",
"      Chronic kidney disease including nephrotic syndrome",
"     </li>",
"     <li>",
"      Cardiac transplantation",
"     </li>",
"     <li>",
"      Kawasaki disease",
"     </li>",
"     <li>",
"      Chronic inflammatory disease",
"     </li>",
"     <li>",
"      Childhood cancer survivors",
"     </li>",
"     <li>",
"      Congenital heart disease",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a scientific statement from the American Heart Association (AHA), a panel of experts reviewed the literature on premature CVD in children and established a disease risk stratification schema for coronary artery disease (CAD), which was revised into a two-tier schema by the National Heart, Lung, and Blood Institute panel in 2011 (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk stratification based on specific diseases'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=see_link&amp;anchor=H235228239#H235228239\">",
"     \"Definition and screening for dyslipidemia in children\", section on 'Lipid screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This schema separated the above diseases into high and moderate risk categories for CVD as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &ndash; Pathologic or clinical evidence of CAD before 30 years of age. Diseases in this category include types 1 and 2 diabetes mellitus, chronic kidney disease, heart transplant recipients, and Kawasaki disease with current coronary aneurysms.",
"     </li>",
"     <li>",
"      Moderate risk &ndash; Pathophysiologic evidence for accelerated atherosclerosis before 30 years of life. Diseases in this category include Kawasaki disease with regressed coronary aneurysms, chronic inflammatory disease, HIV infection, and nephrotic syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of children with the above disorders includes treatment of their underlying disease and interventions targeting comorbid conditions, such as overweight, hypertension, or dyslipidemia. Thresholds for initiating therapy for comorbidities are dependent on the child's assessed risk for CVD. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Approach to management'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/1\">",
"      American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007; 119:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/2\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/3\">",
"      Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/4\">",
"      Haller MJ, Stein J, Shuster J, et al. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatr Diabetes 2007; 8:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/5\">",
"      Haller MJ, Stein JM, Shuster JJ, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009; 22:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/6\">",
"      Nayir A, Bilge I, Kili&ccedil;aslan I, et al. Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant 2001; 16:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/7\">",
"      Litwin M, Grenda R, Prokurat S, et al. Patient survival and causes of death on hemodialysis and peritoneal dialysis--single-center study. Pediatr Nephrol 2001; 16:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/8\">",
"      Mitsnefes MM, Kimball TR, Witt SA, et al. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation 2003; 107:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/9\">",
"      Hussein G, Bughdady Y, Kandil ME, et al. Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure. Pediatr Nephrol 2008; 23:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/10\">",
"      Litwin M, W&uuml;hl E, Jourdan C, et al. Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrol Dial Transplant 2008; 23:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/11\">",
"      Covic A, Mardare N, Gusbeth-Tatomir P, et al. Increased arterial stiffness in children on haemodialysis. Nephrol Dial Transplant 2006; 21:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/12\">",
"      Bakiler AR, Yavascan O, Harputluoglu N, et al. Evaluation of aortic stiffness in children with chronic renal failure. Pediatr Nephrol 2007; 22:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/13\">",
"      Fassett RG, Ball MJ, Robertson IK, et al. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol 2008; 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/14\">",
"      Pahl E, Zales VR, Fricker FJ, Addonizio LJ. Posttransplant coronary artery disease in children. A multicenter national survey. Circulation 1994; 90:II56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/15\">",
"      Dent CL, Canter CE, Hirsch R, Balzer DT. Transplant coronary artery disease in pediatric heart transplant recipients. J Heart Lung Transplant 2000; 19:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/16\">",
"      Kuhn MA, Jutzy KR, Deming DD, et al. The medium-term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation. J Am Coll Cardiol 2000; 36:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/17\">",
"      Dalla Pozza R, Bechtold S, Urschel S, et al. Subclinical atherosclerosis, but normal autonomic function after Kawasaki disease. J Pediatr 2007; 151:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/18\">",
"      Yamakawa R. The vascular function of the long-term coronary artery after Kawasaki disease--evaluation by intracoronary injection of acetylcholine. Kurume Med J 1997; 44:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/19\">",
"      Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/20\">",
"      Nakamura Y, Aso E, Yashiro M, et al. Mortality among persons with a history of kawasaki disease in Japan: mortality among males with cardiac sequelae is significantly higher than that of the general population. Circ J 2008; 72:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/21\">",
"      McCrindle BW, McIntyre S, Kim C, et al. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis? J Pediatr 2007; 151:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/22\">",
"      Gupta-Malhotra M, Gruber D, Abraham SS, et al. Atherosclerosis in survivors of Kawasaki disease. J Pediatr 2009; 155:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/23\">",
"      Cheung YF, Yung TC, Tam SC, et al. Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol 2004; 43:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/24\">",
"      Roberts WC. Major anomalies of coronary arterial origin seen in adulthood. Am Heart J 1986; 111:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/25\">",
"      Dhillon R, Clarkson P, Donald AE, et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/26\">",
"      Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/27\">",
"      Gordon JB, Kahn AM, Burns JC. When children with kawasaki disease grow up myocardial and vascular complications in adulthood. J Am Coll Cardiol 2009; 54:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/28\">",
"      Gersony WM. The adult after kawasaki disease the risks for late coronary events. J Am Coll Cardiol 2009; 54:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/29\">",
"      Ilowite NT, Copperman N, Leicht T, et al. Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 1995; 22:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/30\">",
"      Schanberg LE, Sandborg C, Barnhart HX, et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009; 60:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/31\">",
"      Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339:b4606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/32\">",
"      Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008; 121:e387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/33\">",
"      Neville KA, Cohn RJ, Steinbeck KS, et al. Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab 2006; 91:4401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/34\">",
"      Green DM, Hyland A, Chung CS, et al. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol 1999; 17:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/35\">",
"      Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003; 21:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/36\">",
"      Birkebaek NH, Fisker S, Clausen N, et al. Growth and endocrinological disorders up to 21 years after treatment for acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 1998; 30:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/37\">",
"      Lipshultz SE, Lipsitz SR, Hinkle AS, et al. Cardiovascular status, subsequent risk, and associated factors in long-term survivors of childhood cancer in a population-based study. Circulation 2005; 112 (Suppl 2):476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/38\">",
"      Steinberger J, Sinaiko AR, Kelly AS, et al. Cardiovascular risk and insulin resistance in childhood cancer survivors. J Pediatr 2012; 160:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/39\">",
"      Pinto NM, Marino BS, Wernovsky G, et al. Obesity is a common comorbidity in children with congenital and acquired heart disease. Pediatrics 2007; 120:e1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/40\">",
"      Click RL, Holmes DR Jr, Vlietstra RE, et al. Anomalous coronary arteries: location, degree of atherosclerosis and effect on survival--a report from the Coronary Artery Surgery Study. J Am Coll Cardiol 1989; 13:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/41\">",
"      Ou P, Mousseaux E, Azarine A, et al. Detection of coronary complications after the arterial switch operation for transposition of the great arteries: first experience with multislice computed tomography in children. J Thorac Cardiovasc Surg 2006; 131:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/42\">",
"      Pedra SR, Pedra CA, Abizaid AA, et al. Intracoronary ultrasound assessment late after the arterial switch operation for transposition of the great arteries. J Am Coll Cardiol 2005; 45:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/43\">",
"      Gagliardi MG, Adorisio R, Crea F, et al. Abnormal vasomotor function of the epicardial coronary arteries in children five to eight years after arterial switch operation: an angiographic and intracoronary Doppler flow wire study. J Am Coll Cardiol 2005; 46:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/44\">",
"      Pasquali SK, Marino BS, Pudusseri A, et al. Risk factors and comorbidities associated with obesity in children and adolescents after the arterial switch operation and Ross procedure. Am Heart J 2009; 158:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40184/abstract/45\">",
"      Vriend JW, de Groot E, de Waal TT, et al. Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair. Am Heart J 2006; 151:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5762 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40184=[""].join("\n");
var outline_f39_15_40184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK STRATIFICATION BASED ON SPECIFIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FAMILIAL HYPERCHOLESTEROLEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIABETES MELLITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CARDIAC TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      KAWASAKI DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHRONIC INFLAMMATORY DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CANCER SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONGENITAL HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5762|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5762|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?35/29/36318\" title=\"movie 1\">",
"      Ascending aorta in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?18/43/19134\" title=\"movie 2\">",
"      Left coronary artery in Kawasaki disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/14/36070?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/60/35782?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 3\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 4\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/12/31943?source=related_link\">",
"      Cardiac abnormalities in children and adolescents with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=related_link\">",
"      Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=related_link\">",
"      Definition and screening for dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/25000?source=related_link\">",
"      Lipid abnormalities after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=related_link\">",
"      Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=related_link\">",
"      Overview of the management of the child at risk for atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/25/44441?source=related_link\">",
"      Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/35/4660?source=related_link\">",
"      Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/12/42184?source=related_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_15_40185="Cervical cytology: Interpretation of results";
var content_f39_15_40185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical cytology: Interpretation of results",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/15/40185/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/15/40185/contributors\">",
"     Christine H Holschneider, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/15/40185/contributors\">",
"     Christopher P Crum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/15/40185/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/15/40185/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/15/40185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/15/40185/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/15/40185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cytology became the standard screening test for cervical cancer and premalignant cervical lesions with the introduction of the Papanicolaou (Pap) smear in 1941 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/1\">",
"     1",
"    </a>",
"    ]. Liquid-based, thin layer preparation (eg, ThinPrep&reg;, SurePath&trade;) of cervical cytology specimens was a subsequent modification in technique. Terminology for reporting cervical cytology was standardized by the Bethesda System in 1988 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/2\">",
"     2",
"    </a>",
"    ]. This system has been revised several times and the current system was developed in 2001 (",
"    <a class=\"graphic graphic_table graphicRef71416 \" href=\"mobipreview.htm?18/51/19261\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interpretation of cervical cytology results will be reviewed here. Cervical cancer screening strategies and techniques, as well as the follow-up of abnormal cytology results and treatment of cervical intraepithelial neoplasia, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=see_link\">",
"     \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY FOR SQUAMOUS CELL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been frequent modifications in the nomenclature used for classifying cytologic and histologic cervical changes associated with human papillomavirus (HPV) infection and precancerous lesions. The current classification system in the United States was introduced with the Bethesda 1988 System [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major shifts in terminology apply to squamous cell abnormalities. The corresponding terms across the three current and previous terminology systems for squamous cell abnormalities are shown in the table (",
"    <a class=\"graphic graphic_figure graphicRef60116 \" href=\"mobipreview.htm?4/20/4423\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Squamous cervical cytologic abnormalities (those detected with Pap tests) are reported using the term cervical squamous intraepithelial lesions (CSIL). Specifying \"cervical\" differentiates these lesions from anal squamous intraepithelial lesions, which use similar terminology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1562?source=see_link\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CSIL is stratified into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low grade squamous intraepithelial lesion (LSIL)",
"     </li>",
"     <li>",
"      High grade squamous intraepithelial lesion (HSIL)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The shift in terminology to LSIL and HSIL was made in the Bethesda 1988 system in recognition of the differing clinical course of these two levels of cellular change. LSIL, especially in young women, is generally a transient HPV infection, whereas HSIL is more likely to be associated with persistent HPV infection and a higher risk of progression to cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytologic abnormalities must be further evaluated with colposcopy and biopsy. The finding of LSIL versus HSIL on cytology does not constitute a diagnosis of cervical intraepithelial lesion (CIN) 1 versus CIN 2 or 3, respectively. Cytologic findings may be associated with a subsequent histologic finding that is either more or less severe.",
"   </p>",
"   <p>",
"    Current terminology for histologic squamous cell abnormalities is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link&amp;anchor=H1#H1\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Terminology'",
"    </a>",
"    ). Current terminology for glandular cell findings is described in a section below (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Glandular cell abnormalities'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROLE OF CERVICAL CYTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of cervical cytology tests cannot be used to make a definitive diagnosis or initiate treatment. Rather, the test functions solely to screen for cellular abnormalities that are associated with an increased risk for the development of cervical cancer. Thus, it selects those women who should have further evaluation, such as colposcopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy. Approximately 7 to 10 percent of women who are screened require additional evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/6\">",
"     6",
"    </a>",
"    ]. Treatment decisions are then made based upon diagnostic results from histologic examination, usually from colposcopically directed biopsies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THE CERVICAL CYTOLOGY REPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cervical cytology report consists of (",
"    <a class=\"graphic graphic_table graphicRef71416 \" href=\"mobipreview.htm?18/51/19261\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A description of specimen type and test requested &mdash; cervical or vaginal sample, conventional Pap smear, liquid based cytology,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reflex HPV test",
"     </li>",
"     <li>",
"      A description of specimen adequacy",
"     </li>",
"     <li>",
"      A general categorization (optional) &mdash; negative, epithelial cell abnormality, or other",
"     </li>",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       interpretation/result",
"      </span>",
"      &mdash; either the specimen is negative for intraepithelial lesions and malignancy (although organisms or reactive changes may be present) or there is an epithelial cell abnormality as defined by the Bethesda 2001 classification or there is another finding. This latter category may indicate some increased risk, as an example: endometrial cells in a woman over 40 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A description of any ancillary testing or automated review that was performed (eg, HPV, AutoPap)",
"     </li>",
"     <li>",
"      Educational notes and suggestions by the pathologist (optional)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SPECIMEN ADEQUACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Satisfactory cervical cytology is defined by the number of squamous cells in the sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Satisfactory for evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for \"satisfactory for evaluation\" are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squamous cellularity &mdash; conventional Pap smears must have at least 8000 to 12,000 well-visualized squamous cells; liquid-based preparations must have a minimum of 5000 well-visualized squamous cells",
"     </li>",
"     <li>",
"      Labeled specimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cellularity may be diminished in women who have been treated with pelvic radiation. This information should be included in the cytology requisition, and the reporting of results will depend on the clinical context and the ability of the laboratory to evaluate the specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical cytology specimens that are designated \"satisfactory for evaluation\" may, in addition, be described using what are referred to as \"quality indicators\". Quality indicators include scant cellularity, partially obscuring blood or inflammation, poor fixation, thickly smeared slides, and absence of endocervical or transformation zone",
"    <span class=\"nowrap\">",
"     (EC/TZ)",
"    </span>",
"    component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Endocervical cell/transformation zone component",
"    </span>",
"    &nbsp;&mdash;&nbsp;A notation is made regarding the presence or absence of an endocervical",
"    <span class=\"nowrap\">",
"     cell/transformation",
"    </span>",
"    zone",
"    <span class=\"nowrap\">",
"     (EC/TZ)",
"    </span>",
"    component, but these cells are not required for a cervical cytology test to be classified as satisfactory according to Bethesda 2001 criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"     4",
"    </a>",
"    ]. The criteria for an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component is at least 10 well-preserved endocervical or squamous metaplastic cells; clusters of cells are not required as they were in Bethesda guidelines prior to 2001.",
"   </p>",
"   <p>",
"    The presence of metaplastic and endocervical cells gives an indication of the sampling of the transformation zone of the cervix (junction of squamous and glandular cells, generally at the external cervical os). The transformation zone is the area at greatest risk for neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/9\">",
"     9",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component is more likely to be absent in adolescents and women older than 30 years, particularly postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance for cervical cancer screening of the absence of the",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component in a cervical cytology specimen is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/7,10,12-15\">",
"     7,10,12-15",
"    </a>",
"    ]. In specimens that lack endocervical cells, cytologic evaluation yields a lower rate of cellular abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/10,12,14\">",
"     10,12,14",
"    </a>",
"    ]. This was best illustrated in a prospective study of over 4000 women in whom cervical cytology specimens without an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component were found to have a significantly lower detection rate of epithelial abnormalities than specimens with an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component (11 versus 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since cytologic abnormalities are the indication for further evaluation with colposcopy and cervical biopsy, this raises the question of whether a histologic diagnosis of cervical intraepithelial neoplasia (CIN) or cervical cancer will be missed in women in whom a Pap test lacks an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component. However, there appears to be no increase in the development of high-grade CIN or cancer in these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/10,15-17\">",
"     10,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When cervical cytology is repeated in women who have had a Pap test without an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component, data suggest that there is no increase in cellular abnormalities compared with other women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. This was illustrated in the prospective study of 4000 women described in a preceding paragraph, repeat cytology performed after a median of 60 days (range 13 to 991 days) showed no significant difference in the rate of epithelial abnormalities in women without versus with an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component on the initial specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, longitudinal studies (six months to eight years of follow-up) of 40,000 to 60,000 women with a Pap test that was reported as negative for epithelial abnormalities but lacked an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component found no increase in histologic diagnoses of high-grade CIN or cervical cancer compared with women with an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component (in one study, for high-grade CIN, 0.6 to 2.6 versus 2.9 per 1000 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/15\">",
"     15",
"    </a>",
"    ]; in the other study, for high-grade CIN, 6.2 versus 6.1 per 1000 and for cervical cancer, 0.53 versus 0.54 per 1000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/17\">",
"     17",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    On the other hand, the proportion of endocervical adenocarcinoma among all cervical carcinomas is increasing. Since these cancers most commonly arise in the glandular cells of the endocervix, it is plausible that the detection of such cancers may be reduced in specimens that lack an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/19\">",
"     19",
"    </a>",
"    ]. However, glandular abnormalities are less common than squamous abnormalities and there are few data to support or refute this concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/15,20\">",
"     15,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advent of testing for HPV strains that are associated with a high risk of cervical neoplasia (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"mobipreview.htm?0/27/443\">",
"     table 2",
"    </a>",
"    ) has not clarified this issue. A potentially clinically important subgroup is women with a negative cervical cytology specimen that lacks an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component who have negative cytology and a positive HPV test. It is unknown whether abnormal endocervical cells may have been missed in these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/7\">",
"     7",
"    </a>",
"    ]. It appears that women with a negative Pap test and positive HPV appear to have an increased risk for subsequent cervical neoplasia; however, studies of this issue do not report the rate of Paps without an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with an inadequate",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component and a negative HPV test, the issue is whether the lack of these cells decreases the sensitivity of the HPV test. Two retrospective series from the same institution of over 26,000 negative cervical cytology specimens that were tested for high-risk HPV found no significant difference in the prevalence of HPV in specimens without or with an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component (2.5 versus 2.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/11,22\">",
"     11,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A task force of the American Society for Colposcopy and Cervical Pathology addressing the issue of cervical cytology specimens lacking an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    zone recommended that most women without an",
"    <span class=\"nowrap\">",
"     EC/TZ",
"    </span>",
"    component be screened with a repeat Pap test in 12 months and not to wait longer for a repeat test, even for women who would otherwise be candidates for less frequent screening&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/7\">",
"     7",
"    </a>",
"    ]. However, repeat cervical cytology in six months was advised in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A previous cervical cytology test result of atypical squamous cells of undetermined significance (ASC-US) or worse without two subsequent negative cervical cytology tests or a subsequent negative HPV test",
"     </li>",
"     <li>",
"      A previous cervical cytology test with an unexplained glandular abnormality",
"     </li>",
"     <li>",
"      A positive test for a high risk HPV strain within the previous 12 months (",
"      <a class=\"graphic graphic_table graphicRef76394 \" href=\"mobipreview.htm?0/27/443\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inability to clearly visualize or sample the endocervical canal",
"     </li>",
"     <li>",
"      Similar obscuring factor in consecutive Pap tests",
"     </li>",
"     <li>",
"      Insufficient frequency of previous screening",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Partially obscuring blood or inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specimen is considered \"partially obscured\" when 50 to 75 percent of the epithelial cells cannot be visualized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"     4",
"    </a>",
"    ]. Specimens in which more than 75 percent of the cells are obscured are designated unsatisfactory (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Unsatisfactory for evaluation'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Women with partially obscuring blood or inflammation should have a repeat test in six months if they meet any of the above risk criteria or have a similar factor obscuring consecutive tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/23\">",
"     23",
"    </a>",
"    ]. This includes women whose tests are otherwise satisfactory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Unsatisfactory for evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cytology tests that are designated \"unsatisfactory for evaluation\" for one of three reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Scanty cellularity",
"     </li>",
"     <li>",
"      Obscuring inflammation or blood",
"     </li>",
"     <li>",
"      Unlabeled or otherwise unable to be processed by the laboratory",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason for finding a specimen in unsatisfactory is noted in the report. The criteria for cellularity and obscuring inflammation or blood are noted in the preceding sections (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Satisfactory for evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Partially obscuring blood or inflammation'",
"    </a>",
"    above). Specimens that were not processed by the laboratory because they were unlabeled or the vial or slide broke are distinguished from specimens determined to be unsatisfactory after processing.",
"   </p>",
"   <p>",
"    An unsatisfactory cervical cytology specimen is considered unreliable for the evaluation of epithelial abnormalities. Whether women with unsatisfactory cervical cytology tests are more likely to have intraepithelial lesions or cancer on follow-up than women with satisfactory tests is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Society for Colposcopy and Cervical Pathology and the National Comprehensive Cancer Network recommend that most women with cervical cytology that was unsatisfactory for evaluation be screened with a repeat Pap test within six weeks to four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/7,27\">",
"     7,27",
"    </a>",
"    ]. A short interval between Pap tests (15 to 30 days) does not appear to affect sensitivity for detection of cervical neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link&amp;anchor=H24#H24\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\", section on 'Interval between Pap tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the cells are obscured by inflammation and a specific infection is identified, treatment should be given before repeating the Pap test. Therefore, in women with repeatedly unsatisfactory cytology specimens as well as those with symptoms (eg, postcoital bleeding, pelvic pain) or physical examination findings suggestive of cervical cancer (eg, visible cervical lesion), additional clinical evaluation with colposcopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsies is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=see_link&amp;anchor=H6#H6\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women in with an unsatisfactory Pap test in whom the test was not indicated within an appropriate screening protocol do not need to repeat the test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENERAL CATEGORIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is an optional section where specimens are noted as either \"negative for intraepithelial lesion or malignancy\", \"epithelial cell abnormality\", or \"other\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"     4",
"    </a>",
"    ]. Specimens designated as \"other\" include those that contain no morphologic abnormalities, but the findings may indicate some increased cancer risk (eg, endometrial cells).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INTERPRETATION/RESULT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specimen is reported as either \"negative for intraepithelial lesions or malignancy\" or an epithelial cell abnormality is specified. Reporting of non-neoplastic findings (eg, infection or inflammation) is optional and is reported under the heading \"other\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Negative for intraepithelial lesion or malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are specimens in which no epithelial abnormality is identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intraepithelial cell abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraepithelial abnormalities associated with HPV infection and cervical precancer or cancer (nuclear enlargement and granulation, the presence of koilocytes, an increased nucleocytoplasmic ratio, and frequent mitoses) are specified as defined by the Bethesda 2001 classification.",
"   </p>",
"   <p>",
"    Epithelial cell abnormalities are classified as squamous or glandular (",
"    <a class=\"graphic graphic_table graphicRef71416 \" href=\"mobipreview.htm?18/51/19261\">",
"     table 1",
"    </a>",
"    ). The term \"atypical epithelial cells\" may be used for cases where a squamous versus glandular origin cannot be determined.",
"   </p>",
"   <p>",
"    The categories of epithelial cell abnormalities are discussed below. Follow-up for these abnormalities can be found in the topic reviews listed with each category.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Squamous cell abnormalities",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical squamous cells (ASC) are categorized as either of undetermined significance (ASC-US) or cannot exclude a high-grade squamous intraepithelial lesion (ASC-H). The ASC-H category includes findings that are equivocal, but likely consists of a mixture of true high-grade squamous intraepithelial lesions and other findings that mimic such lesions. Approximately 5 to 10 percent of ASC results are designated ASC-H [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low grade intraepithelial lesion (LSIL). The LSIL category includes changes consistent with HPV, mild dysplasia, or CIN 1 (grade 1 cervical intraepithelial neoplasia).",
"      <br/>",
"      <br/>",
"      LSIL cervical cytologic specimens occasionally contain a few cells that are suspicious for, but not diagnostic of, a high-grade squamous intraepithelial lesion. Retrospective studies have found that these women have a significantly higher likelihood of a high grade lesion on biopsy than other women with LSIL (approximately 30 versus 15 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Although this is not included in the Bethesda classification, some experts report such cytology as LSIL with a statement regarding the presence of a possible high grade abnormality (eg, cannot exclude a high grade lesion, some cells suggestive high grade intraepithelial lesion, or LSIL-H). These women should undergo colposcopy and endocervical sampling. In our practice, we manage these cases like those with a cytologic diagnosis of HSIL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=see_link\">",
"       \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High grade intraepithelial lesion (HSIL). HSIL includes changes consistent with moderate or severe dysplasia, CIN 2 or 3, and carcinoma in situ (CIS) and should indicate if there are features suspicious for invasive disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"       \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Squamous cell carcinoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=see_link\">",
"       \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The LSIL category includes changes consistent with HPV, mild dysplasia, or CIN 1 (grade 1 cervical intraepithelial neoplasia). HSIL includes changes consistent with moderate or severe dysplasia, CIN 2 or 3, and carcinoma in situ (CIS) and should indicate if there are features suspicious for invasive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Glandular cell abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glandular abnormalities on cytology are reported in the Bethesda 2001 classification as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical glandular cells (AGC). Endocervical, endometrial, or not otherwise specified is noted. Upon further evaluation, either high-grade squamous or glandular abnormalities are found in 10 to 39 percent of women with a finding of AGC on cytology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/33\">",
"       33",
"      </a>",
"      ]. This replaces the previous term \"atypical glandular cells of undetermined significance\".",
"     </li>",
"     <li>",
"      Atypical glandular cells, favor neoplastic. Endocervical or not otherwise specified is noted. This designation is for specimens that show features suggestive of, but no sufficient for an interpretation of adenocarcinoma.",
"     </li>",
"     <li>",
"      Endocervical adenocarcinoma in situ (",
"      <strong>",
"       AIS",
"      </strong>",
"      ).",
"     </li>",
"     <li>",
"      Adenocarcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The follow-up of glandular cervical abnormalities is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When glandular cell abnormalities are present, it should be noted whether there are changes favoring neoplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings that are nonneoplastic or are related to cancers other than cervical cancer are noted as \"other\". The presence of endometrial cells in a woman &ge;40 years of age should be noted. Specimens may have additional findings that should be described, such as infectious organisms or cellular changes associated with infection, reactive cellular changes, atrophy, or glandular cells after hysterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Benign-appearing endometrial cells in a woman &ge;40 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bethesda 2001 system reports the presence of normal, cytologically benign-appearing exfoliated endometrial glandular cells only in women &ge;40 years of age (these are not reported for women younger than 40 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"     4",
"    </a>",
"    ]. These are reported regardless of the date of the last menstrual period. Their presence may reflect physiologic shedding (especially in the first half of the menstrual cycle), or shedding in response to a pathological process. The cells are reported so that the clinician can determine the significance of the finding in an individual patient.",
"   </p>",
"   <p>",
"    Benign appearing endometrial cells are noted in up to 12 percent of Pap cervical cytology tests performed over one year, more commonly in premenopausal than postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/34\">",
"     34",
"    </a>",
"    ]. The frequency this finding in women who are older than 40 years or postmenopausal is 0.4 percent of specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/35\">",
"     35",
"    </a>",
"    ]. The prevalence is significantly higher in liquid-based versus conventional cytology (0.9 versus 0.3 percent).",
"   </p>",
"   <p>",
"    The prevalence of a finding of benign-appearing endometrial cells varies with the menstrual cycle. Combined results from two large studies showed that benign appearing endometrial cells are more likely to be identified on cervicovaginal cervical cytology tests in the first 10 to 12 days of the menstrual cycle (prevalence 21 to 24 percent) than in the remainder of the cycle (prevalence 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large reviews of benign-appearing endometrial cells in women over age 40 have reported that 7 to 16 percent of cervical cytology specimens with this finding were associated with significant endometrial pathology (hyperplasia or carcinoma) upon further evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In one of these reviews that included 22 studies, among women with significant pathology, 79 percent also had abnormal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women over age 40 encompass both pre- and postmenopausal women. If symptoms of endometrial cancer are present (abnormal uterine bleeding), the patient should undergo endometrial sampling regardless of menopausal status.",
"   </p>",
"   <p>",
"    In premenopausal women without abnormal bleeding, benign appearing endometrial cells are rarely associated with significant pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/38-44\">",
"     38-44",
"    </a>",
"    ]. Thus, the 2006 Bethesda recommendations suggest no further work-up for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, we offer endometrial sampling to those asymptomatic premenopausal women with benign appearing endometrial cells who are at increased risk for endometrial cancer (eg, family or personal history of ovarian, breast, colon, or endometrial cancer;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    use; chronic anovulation; obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/8\">",
"     8",
"    </a>",
"    ]; estrogen therapy; prior endometrial hyperplasia; diabetes) (",
"    <a class=\"graphic graphic_table graphicRef62089 \" href=\"mobipreview.htm?38/30/39403\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, asymptomatic postmenopausal women with benign endometrial cells are at higher risk of endometrial cancer. Therefore, endometrial assessment is recommended for this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other types of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of any other types of malignant cells should be described. As an example, the cervical cytology test may occasionally identify malignant cells from the fallopian tube, ovary, peritoneal cavity, vulva, or vagina. This should be kept in mind, especially in women with persistent AGC that remains unexplained after cervical and endometrial evaluation. In these cases, referral to a gynecologic oncologist is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of infection does not preclude further evaluation of an epithelial cell abnormality. When an infectious organism is identified or suggested, the patient should be contacted to determine if she is symptomatic. Antibiotic therapy is indicated for any symptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trichomonas &mdash; Asymptomatic trichomonas infection should be treated if the diagnosis is reasonably certain. Liquid-based cervical cytology for diagnosis of trichomoniasis is more accurate than conventional Pap smears. The sensitivity, specificity, and positive and negative predictive values of liquid-based cervical cytology tests for trichomonas infection are 61, 99, 96, and 91 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/47\">",
"       47",
"      </a>",
"      ]. Therefore, treatment of asymptomatic women with trichomonads noted on liquid-based cervical cytology is a reasonable approach. Conventional Pap smears have a high false positive rate for trichomonads. Therefore, the diagnosis should be confirmed by wet prep in asymptomatic women. However, if the wet prep is negative, then culture is indicated because of the low sensitivity of wet prep for this organism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=see_link\">",
"       \"Trichomonas vaginalis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial vaginosis &mdash; Cervical cytology is not a reliable diagnostic method for bacterial vaginosis (BV) and women with a cytologic report of BV need confirmation with clinical testing before treatment. Further, clinical diagnosis of BV is not associated with CIN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/48\">",
"       48",
"      </a>",
"      ]. However, a cytologic report of BV occurs 10 times more commonly in women with versus without HSIL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/49\">",
"       49",
"      </a>",
"      ]. The clinical significance of this finding is unknown. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=see_link&amp;anchor=H5#H5\">",
"       \"Bacterial vaginosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herpes simplex &mdash; Herpes simplex may produce characteristic cytopathologic changes (multinucleated giant cells). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Actinomyces &mdash; Actinomyces may be identified on cervical cytology tests, typically in women who have an intrauterine device. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"       \"Overview of intrauterine contraception\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chlamydia &mdash; Chlamydia infection cannot be reliably diagnosed by cervical cytology tests [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other non-neoplastic findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1688363\">",
"    <span class=\"h4\">",
"     Reactive changes/inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with only reactive changes due to inflammation will not have an organism identified on their cervical cytology test. The cervical cytology sampling does not need to be repeated unless the patient is HIV positive (or has a history of immunosuppression), in which case it should be repeated in four to six months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36934?source=see_link\">",
"     \"Screening for cervical cancer in HIV infected women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1688371\">",
"    <span class=\"h4\">",
"     Parabasal cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parabasal cell are most likely to be seen prior to menarche or following menopause, when the epithelium is not fully glycogenated. They carry no significance other than being occasionally confused with dysplastic cells due to their immature appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1688356\">",
"    <span class=\"h4\">",
"     Hyperkeratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkeratosis or parakeratosis on an otherwise negative cervical cytology test is not a marker for significant CIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/46,51\">",
"     46,51",
"    </a>",
"    ], and may be related to infection or trauma with inflammation, such as from use of a diaphragm. We do not perform colposcopy based on this finding. We repeat the cervical cytology test in 6 to 12 months, depending upon whether the patient is at increased risk for CIN, such as immunocompromised or age less than 30. If hyperkeratosis persists, treatment with topical estrogen may resolve the finding, but no treatment is necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9531307\">",
"    <span class=\"h1\">",
"     FOLLOW-UP OF CYTOLOGIC RESULTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Normal cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up of patients with a normal result on cervical cytology is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2338375445\">",
"    <span class=\"h3\">",
"     HPV positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with normal cytology and positive testing for high-risk strains of human papilloma virus (HPV) may be further evaluated either with cytology and HPV testing at 12 months or with genotyping for HPV",
"    <span class=\"nowrap\">",
"     16/18,",
"    </span>",
"    the strains that are associated with the highest risk of cervical cancer (",
"    <a class=\"graphic graphic_algorithm graphicRef61527 \" href=\"mobipreview.htm?40/32/41473\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef54413 \" href=\"mobipreview.htm?33/14/34021\">",
"     algorithm 2",
"    </a>",
"    ). If the patient is positive for HPV",
"    <span class=\"nowrap\">",
"     16/18,",
"    </span>",
"    she should be evaluated with colposcopy with endocervical curettage (ECC). ECC is required because normal cytology with persistent positive HPV can be associated with",
"    <span class=\"nowrap\">",
"     endocervical/glandular",
"    </span>",
"    abnormalities, which are less reliably detected by colposcopy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H8372719#H8372719\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Normal Pap smear and positive HPV test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If cervical intraepithelial neoplasia is identified, the patient should be managed as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the colposcopy and ECC are negative, the cytology and HPV testing are repeated in 12 months. There are no guidelines regarding management if the HPV is persistently positive in the setting of negative findings on cytology, colposcopy, and ECC. In our practice, we manage such patients depending upon risk factors and history regarding cervical cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If she has a history of normal cervical cytology but annual positive HPV testing, the options are to continue annual cytology and HPV testing and repeat colposcopy only if a cytologic abnormality is found OR to repeat colposcopy annually. &nbsp;&nbsp;",
"     </li>",
"     <li>",
"      If she has a history of cytology with atypical squamous cells or low grade squamous intraepithelial lesion, in our practice, we repeat colposcopy annually.",
"     </li>",
"     <li>",
"      If she has a history of cytology with high grade squamous intraepithelial lesion or atypical glandular cells, we repeat colposcopy every six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Abnormal cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significant cytological abnormalities need further evaluation, which may include repeat cytology, human papillomavirus testing, or colposcopy. Evaluation of the results of cervical cytology is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=see_link\">",
"     \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9531352\">",
"    <span class=\"h1\">",
"     VAGINAL CYTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following total hysterectomy (removal of the uterus and cervix), vaginal cytology is",
"    <strong>",
"     not",
"    </strong>",
"    required for most women. Vaginal cancer is rare (1 per 100,000 women) and vaginal cytology should be performed only in women who are at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H26#H26\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Prior hysterectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H36#H36\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Women who have undergone hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of vaginal intraepithelial neoplasia (VAIN) or vaginal cancer is extremely low in women who have undergone total hysterectomy for benign disease (excluding cervical intraepithelial neoplasia [CIN] 2,3), and for this reason, screening guidelines in the United States (US) from the US Preventive Services Task Force (USPSTF), the American Cancer Society (ACS), and the American College of Obstetricians and Gynecologists (ACOG) concur that these women do not need post-hysterectomy vaginal cytology.",
"   </p>",
"   <p>",
"    Human papillomavirus (HPV) is the etiologic agent of most vaginal cancers, as well as other anogenital malignancies. Women who are immunosuppressed have decreased rates of clearance of HPV infection. In addition, women exposed to diethylstilbestrol (DES) in utero are at risk of developing vaginal clear cell adenocarcinoma. Thus, vaginal cytology for vaginal cancer screening is advisable for women who have undergone total hysterectomy who have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior vaginal cancer (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31208?source=see_link&amp;anchor=H19#H19\">",
"       \"Vaginal cancer\", section on 'Posttreatment surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior cervical, vulvar, or anal cancer (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/42/17064?source=see_link&amp;anchor=H7#H7\">",
"       \"Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance\", section on 'Surveillance strategies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20714?source=see_link&amp;anchor=H25#H25\">",
"       \"Vulvar cancer: Staging, treatment, and prognosis\", section on 'Posttreatment surveillance'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38762?source=see_link&amp;anchor=H441718822#H441718822\">",
"       \"Clinical features, staging, and treatment of anal cancer\", section on 'Posttreatment surveillance'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      CIN 2,3 or cervical adenocarcinoma in-situ prior to, or diagnosed at the time of total hysterectomy (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link&amp;anchor=H31#H31\">",
"       \"Cervical intraepithelial neoplasia: Management\", section on 'Post-hysterectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In utero exposure to diethylstilbestrol (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=see_link&amp;anchor=H4#H4\">",
"       \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\", section on 'Clear cell adenocarcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunosuppression (eg, human immunodeficiency infection, history of solid organ or hematopoietic cell transplant) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H15399523#H15399523\">",
"       \"Screening for cervical cancer: Rationale and recommendations\", section on 'Immunocompromised women'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If vaginal cytology is performed, the findings are reported in the same manner as cervical cytology. The indications for further evaluation with vaginal colposcopy are the same as for performing colposcopy following abnormal findings of cervical cytology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=see_link\">",
"     \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link&amp;anchor=H16#H16\">",
"     \"Colposcopy\", section on 'Vaginal colposcopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benign glandular cells are seen in less than two percent of post-hysterectomy specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/15/40185/abstract/53\">",
"     53",
"    </a>",
"    ]. They are presumed to be the consequence of either columnar metaplasia or reactive phenomena. They do not require further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/53/8019?source=see_link\">",
"       \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unsatisfactory cervical cytology tests should be repeated in two to four months. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Unsatisfactory for evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with insufficient endocervical cells in an otherwise satisfactory specimen can be screened with a repeat test in 12 months. Repeat testing in six months is suggested for such women who have risk factors for cervical cancer. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Endocervical cell/transformation zone component'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraepithelial abnormalities and glandular abnormalities require further assessment to exclude cancer or a precancerous lesion. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Intraepithelial cell abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with normal cytology and positive testing for high-risk strains of human papilloma virus (HPV) may be further evaluated either with cytology and HPV testing at 12 months or with genotyping for HPV",
"      <span class=\"nowrap\">",
"       16/18,",
"      </span>",
"      the strains that are associated with the highest risk of cervical cancer (",
"      <a class=\"graphic graphic_algorithm graphicRef61527 \" href=\"mobipreview.htm?40/32/41473\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef54413 \" href=\"mobipreview.htm?33/14/34021\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2338375445\">",
"       'HPV positive'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infectious organisms may be identified as an incidental finding. Management depends on factors such as whether the patient is symptomatic and the type of infection. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Organisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Bethesda 2001 system reports the presence of normal, cytologically benign-appearing exfoliated endometrial glandular cells only in women &ge;40 years of age (these are not reported for women younger than 40 years). For patients who are &ge;40 years and have a cervical cytology test showing benign appearing endometrial cells, we suggest an endometrial biopsy ONLY in those who have symptoms of endometrial cancer (abnormal uterine bleeding) or risk factors for endometrial cancer (eg, postmenopausal; family or personal history of ovarian, breast, colon, or endometrial cancer;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      use; chronic anovulation; obesity; estrogen therapy; prior endometrial hyperplasia); women without these factors can continue routine gynecologic care. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Benign-appearing endometrial cells in a woman &ge;40 years'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/1\">",
"      Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941; 42:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/2\">",
"      The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 1989; 262:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/3\">",
"      Broder S. From the National Institutes of Health. JAMA 1992; 267:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/4\">",
"      Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/5\">",
"      Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/6\">",
"      Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000; 124:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/7\">",
"      Davey DD, Cox JT, Austin RM, et al. Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection. J Low Genit Tract Dis 2008; 12:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/8\">",
"      Joste N. Overview of the cytology laboratory: specimen processing through diagnosis. Obstet Gynecol Clin North Am 2008; 35:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/9\">",
"      Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/10\">",
"      Baer A, Kiviat NB, Kulasingam S, et al. Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry? Obstet Gynecol 2002; 99:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/11\">",
"      Zhao C, Austin RM. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. Cancer 2008; 114:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/12\">",
"      Vooijs PG, Elias A, van der Graaf Y, Veling S. Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears. Acta Cytol 1985; 29:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/13\">",
"      Kivlahan C, Ingram E. Papanicolaou smears without endocervical cells. Are they inadequate? Acta Cytol 1986; 30:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/14\">",
"      Martin-Hirsch P, Lilford R, Jarvis G, Kitchener HC. Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet 1999; 354:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/15\">",
"      Mitchell HS. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. Cancer 2001; 93:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/16\">",
"      Mitchell H, Medley G. Longitudinal study of women with negative cervical smears according to endocervical status. Lancet 1991; 337:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/17\">",
"      Bos AB, van Ballegooijen M, Elske van den Akker-van Marle M, et al. Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears. Am J Clin Pathol 2001; 115:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/18\">",
"      Tacken MA, Braspenning JC, Mulder J, et al. Loss to follow-up of cervical smears without endocervical columnar cells is not disturbing. Eur J Gynaecol Oncol 2006; 27:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/19\">",
"      Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000; 78:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/20\">",
"      Mitchell H, Hocking J, Saville M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study. Acta Cytol 2004; 48:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/21\">",
"      Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002; 95:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/22\">",
"      Bansal M, Austin RM, Zhao C. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older. Gynecol Oncol 2009; 115:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/23\">",
"      Davey DD, Austin RM, Birdsong G, et al. ASCCP Patient Management Guidelines: Pap Test Specimen Adequacy and Quality Indicators. J Low Genit Tract Dis 2002; 6:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/24\">",
"      Hock YL, Ramaiah S, Wall ES, et al. Outcome of women with inadequate cervical smears followed up for five years. J Clin Pathol 2003; 56:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/25\">",
"      Ransdell JS, Davey DD, Zaleski S. Clinicopathologic correlation of the unsatisfactory Papanicolaou smear. Cancer 1997; 81:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/26\">",
"      Adams AL, Gidley J, Roberson J, et al. Clinical significance of unsatisfactory conventional pap smears owing to inadequate squamous cellularity defined by the Bethesda 2001 criterion. Am J Clin Pathol 2005; 123:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/27\">",
"      Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/28\">",
"      Sherman ME, Solomon D, Schiffman M, ASCUS LSIL Triage Study Group. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am J Clin Pathol 2001; 116:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/29\">",
"      Quddus MR, Sung CJ, Steinhoff MM, et al. Atypical squamous metaplastic cells: reproducibility, outcome, and diagnostic features on ThinPrep Pap test. Cancer 2001; 93:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/30\">",
"      Sherman ME, Tabbara SO, Scott DR, et al. \"ASCUS, rule out HSIL\": cytologic features, histologic correlates, and human papillomavirus detection. Mod Pathol 1999; 12:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/31\">",
"      Nasser SM, Cibas ES, Crum CP, Faquin WC. The significance of the Papanicolaou smear diagnosis of low-grade squamous intraepithelial lesion cannot exclude high-grade squamous intraepithelial lesion. Cancer 2003; 99:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/32\">",
"      Alsharif M, Kjeldahl K, Curran C, et al. Clinical significance of the diagnosis of low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion. Cancer 2009; 117:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/33\">",
"      Jones BA, Novis DA. Cervical biopsy-cytology correlation. A College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories. Arch Pathol Lab Med 1996; 120:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/34\">",
"      Fadare O, Ghofrani M, Chacho MS, Parkash V. The significance of benign endometrial cells in cervicovaginal smears. Adv Anat Pathol 2005; 12:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/35\">",
"      Canfell K, Kang YJ, Clements M, et al. Normal endometrial cells in cervical cytology: systematic review of prevalence and relation to significant endometrial pathology. J Med Screen 2008; 15:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/36\">",
"      Vooijs GP, van der Graaf Y, Vooijs MA. The presence of endometrial cells in cervical smears in relation to the day of the menstrual cycle and the method of contraception. Acta Cytol 1987; 31:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/37\">",
"      LIU W, BARROW MJ, SPITLER MF, KOCHIS AF. NORMAL EXFOLIATION OF ENDOMETRIAL CELLS IN PREMENOPAUSAL WOMEN. Acta Cytol 1963; 7:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/38\">",
"      Bean SM, Connolly K, Roberson J, et al. Incidence and clinical significance of morphologically benign-appearing endometrial cells in patients age 40 years or older: the impact of the 2001 Bethesda System. Cancer 2006; 108:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/39\">",
"      Greenspan DL, Cardillo M, Davey DD, et al. Endometrial cells in cervical cytology: review of cytological features and clinical assessment. J Low Genit Tract Dis 2006; 10:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/40\">",
"      Thrall MJ, Kjeldahl KS, Savik K, et al. Significance of benign endometrial cells in papanicolaou tests from women aged &gt;or=40 years. Cancer 2005; 105:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/41\">",
"      Simsir A, Carter W, Elgert P, Cangiarella J. Reporting endometrial cells in women 40 years and older: assessing the clinical usefulness of Bethesda 2001. Am J Clin Pathol 2005; 123:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/42\">",
"      Ashfaq R, Sharma S, Dulley T, et al. Clinical relevance of benign endometrial cells in postmenopausal women. Diagn Cytopathol 2001; 25:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/43\">",
"      Chang A, Sandweiss L, Bose S. Cytologically benign endometrial cells in the papanicolaou smears of postmenopausal women. Gynecol Oncol 2001; 80:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/44\">",
"      Beal HN, Stone J, Beckmann MJ, McAsey ME. Endometrial cells identified in cervical cytology in women &gt; or = 40 years of age: criteria for appropriate endometrial evaluation. Am J Obstet Gynecol 2007; 196:568.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/45\">",
"      Aslan DL, Crapanzano JP, Harshan M, et al. The Bethesda System 2001 recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers. Gynecol Oncol 2007; 107:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/46\">",
"      Zahn CM, Askew AW, Hall KL, Barth WH Jr. The significance of hyperkeratosis/parakeratosis on otherwise normal Papanicolaou smears. Am J Obstet Gynecol 2002; 187:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/47\">",
"      Lara-Torre E, Pinkerton JS. Accuracy of detection of trichomonas vaginalis organisms on a liquid-based papanicolaou smear. Am J Obstet Gynecol 2003; 188:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/48\">",
"      Peters N, Van Leeuwen AM, Pieters WJ, et al. Bacterial vaginosis is not important in the etiology of cervical neoplasia: a survey on women with dyskaryotic smears. Sex Transm Dis 1995; 22:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/49\">",
"      Klomp JM, Boon ME, Van Haaften M, Heintz AP. Cytologically diagnosed Gardnerella vaginalis infection and cervical (pre)neoplasia as established in population-based cervical screening. Am J Obstet Gynecol 2008; 199:480.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/50\">",
"      Pandit AA, Klhilnani PH, Powar HS, et al. Value of Papanicolaou smear in detection of Chlamydia trachomatis infection. Diagn Cytopathol 1993; 9:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/51\">",
"      Cecchini S, Iossa A, Ciatto S, et al. Colposcopic survey of Papanicolaou test-negative cases with hyperkeratosis or parakeratosis. Obstet Gynecol 1990; 76:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/52\">",
"      Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013; 208:184.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/15/40185/abstract/53\">",
"      Tambouret R, Pitman MB, Bell DA. Benign glandular cells in posthysterectomy vaginal smears. Acta Cytol 1998; 42:1403.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3205 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40185=[""].join("\n");
var outline_f39_15_40185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY FOR SQUAMOUS CELL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROLE OF CERVICAL CYTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF THE CERVICAL CYTOLOGY REPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SPECIMEN ADEQUACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Satisfactory for evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Endocervical cell/transformation zone component",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Partially obscuring blood or inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Unsatisfactory for evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENERAL CATEGORIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INTERPRETATION/RESULT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Negative for intraepithelial lesion or malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intraepithelial cell abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Squamous cell abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Glandular cell abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Benign-appearing endometrial cells in a woman &ge;40 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other types of malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other non-neoplastic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1688363\">",
"      Reactive changes/inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1688371\">",
"      Parabasal cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1688356\">",
"      Hyperkeratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9531307\">",
"      FOLLOW-UP OF CYTOLOGIC RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Normal cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2338375445\">",
"      - HPV positive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Abnormal cytology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9531352\">",
"      VAGINAL CYTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3205|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/32/41473\" title=\"algorithm 1\">",
"      HPV DNA testing cervical cancer screening over 30",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?33/14/34021\" title=\"algorithm 2\">",
"      Genotyping HPV HR and cytology in women 30 and over",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3205|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/20/4423\" title=\"figure 1\">",
"      CIN terminology and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3205|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/51/19261\" title=\"table 1\">",
"      Bethesda class cervix cytol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/27/443\" title=\"table 2\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/30/39403\" title=\"table 3\">",
"      Risk factors endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=related_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=related_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38762?source=related_link\">",
"      Clinical features, staging, and treatment of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/42/17064?source=related_link\">",
"      Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36934?source=related_link\">",
"      Screening for cervical cancer in HIV infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20714?source=related_link\">",
"      Vulvar cancer: Staging, treatment, and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_15_40186="Rosacea erythema";
var content_f39_15_40186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77020%7EDERM%2F67890%7EDERM%2F78747%7EPC%2F59815%7EDERM%2F56083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77020%7EDERM%2F67890%7EDERM%2F78747%7EPC%2F59815%7EDERM%2F56083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and telangiectasias are present on the nose, chin, and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory papules and pustules are present on the nose and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papulopustular rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As seen here, rosacea is characterized by inflammatory papules and pustules and telangiectasias located on the central third of the face. Comedones are absent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlr0AXDtFneMKiAcZxzV0SLH9jlm5k8rymOeijr/46f0qjbOrRwTfK22JUYDsoGM/73HWl08q9jdqM/wCjzLPGD1ZOQR+RrnPaSukx8qNBMYpJCAgKsw5OAeOffrVVpmRZHXALHAxzirup7JWtmRWYMmxVA7gDax+q4/KqCiKFy8uGIOeO1I2iRi2eZULsScls9SF/z2q3AoCKzFiv3U2jqarCc43MoyekYORj0JqxBdCMRtMqErkYPQ56YHalY0VyyId0rBsgDliOVUU4GNEEUGXBB+ZeKgjBZSpDfMOSp6e1WfLdYxtVEwu3I/hFDRalYWJUSZFwGk6En7oqxGFCsGzvY/M2eB7VUxuQqnKY69QaniwQpmwsf8KjnJqStySOURtsKjbzgdz71N5zPHgldq8en51GCudzHaO2arMS3Cg7fQnA+tBSinuToVI3DIX27VZDF1CZVVxwijnFVBEJHiX5iTztzwKtQxYjJjUkDI46E+pzQiZWEZ/3ZUjAHv8AL+OOTUEm9QBtOwDGSuM/UU+QJEyl2BPUBemabt8xDIB8vTLcAUjJorsVPzKd+BkYHApghBTckSL6MvB/DFXEO0AhFb2Iwv4UjoC/zOFJ684C/jSsQzPlt9q5JlYnou85/KqqJvyE3Kg4yTnmtGUM7BIQSPUDn8KbsWCPJAJI6dz/AJ9aZHKUvs4ZslQvGcdAaUBYHAG15f7vUj61MqNK6ovzMxwoU5qKRlhdlXaWBxtHrTE4iyt5n+ucjHZFxx/WqzyRRp+75J6fLU3lyTAvcMQBkgA8KKTy0GNgUEEEHP8ASr3MHBoqEKefOLHvtUgfTFSpcRqwDPtXruC5x9KmmSXeSXbnqRVOaPDpHEQrE9QKLCJhcREMyvI2Pu/LgH61LDPdNnyptg92zj8KpEAgbpCCBwRwaFRjkZJOeBnH6UBZmx/p8xDNK43H720KCaY0MsblZ3iJGT8z9OaySNwChnwOnzGmsi55+XHp3pWQnc2GvhGw2wxy8Z3KpBH0NMF7cvIClngYOF56ms9Z2UbRLIFHQbuKR7i4lIDXM5AGB85J96ANCSSdVy8LRdcFe307VUeQ7iXnaMHrk45/M1BI0jY3lmHbLE/hQIQyEsMd8HHNMNxxdQdyznAOPvdf8RVef7OWIVpHz3C4qdhvJyQM9MD+tNYhAFRef50rjUSszFdpCjf0yxpJN5bCeWhIG7y+je596f8AZzM+GbLNyB6U7yvIJU85/wA9aVyvZjFVdrcSxsOmDnI7iomjXcSTx645P4VYjwWGAfbmlMJJ3enrTuS42IvN8sBRFGfqoNFTrAuOhFFFxWL9kDBGPOAZF+TgdUJ4/I1cRI7O9gkdV8uQbHGcAg8flTzHvvQPL8lLhCFTt5mc5P8AskZNZ11IJS/mlsL8gVeCcDt7VT7mtH+U0oYXeJ9OyftKbtrg9xyAR+Y/GskzeUgWP77D/Wdie/8A+qrkk8mba/IZd6gkr1JX5SMe/r703UbeJLlpVXdBMolhXdjaD1B9wcihm9NmfECroT07A9FHcmr0L5kEwZhg7VlYfnx71Ukd4pCgUNKx4J44/pVhURAWkPQZwDn8qSNW7Gjbzxx4I+6pyfUk+lL5+8FJAUDZIjzyfrVElmeNY4t8h+6v9361Ksc7XDq7oh7szDke1DFFXJju+V3Ukg7R6fhSs5+U4G77q45pITbqP3avK55LN8q/l1qUvjG4pjGFUDAFQaobztUv8xH6U0CTaG3hVB4Xt+FOO4jhdz5PU4yP6CpY0LP8w3MBnA6D3PpQa7DlYyNsclWJwqg4P51aRxtCqQQoyBnge+apyIWcKvKjl2z1Pp9KbIQNqqCI+pPQE9uO9GwnFPYeWQhmXcxHRm/z0pqFnAZmO0Hpjgew9TSBcgmTjJ55/p3qVV+UsTsA/hB5b/69KwuRErN+7DDcingM33j9KgAZkGVRV5GD29/rTogzvkdcY2ZzgUs84i3LF88o6kjIU98UEOHREM7i2jRFOGb36fU1F5bvtkY5yc4z0pFyzEsjyM3P/wBepR5cT/MS5/iANFiXTtsV5SMEDBUHkgfeqKC3/fblUKOo5q0UeaQlyTgcADoKa+35lTcqk/Mfb2oFy9CGVjvOPvE5JA4p5Ax8qjcB65Gf8afkR42BQcfiKrySB9pQE4PHbJp3D2Nx24rkcs/8vqarScOSfmY9QBjH/wBanmZoyFAG/pjrVkW52CXy22dWcEHB9KfMZToWMgxzblfAwx+X35/SrtxCNqvECoC/MpGefUVOoVpd6gE9HyOD6VLcCF/lChCOeCQAfYenek7mfIZIhbkc8HsamEKnduU5HByDn6Vc8o7AVPA53YOB9TUSI28MWwQck0yuS5Va2XaQW+YdvamR20iYz9zr1zmrvkNvHlEkkZYgcg+lKGy5DAFs9cc0hezRWeMqRuU8Unl55OQO1aEcReIllAPYZ6etJ9nLDB+XA4NO4nTRQkj2425Hqab5RZi0g+etGOJTuViduMHjP6U1rXa5x93saGJRtuUCigsVB+vrUMkXmSY6Y6Z9a1RFuOEBOO3eq7w7M4AJJ7CkacpShhO8gnkc9Opq2Ih5fzdTUtujqjbsgHjBpz7QhUH5qDNwuRNCgYgYYDofWipDG3G0gj3ooI5C5fyx3TwMs5JbKE9NoXlPxByKpXbidxcbkJIGFwAEHQBh+mOvSp54o/mkhO1wQqleN7Dnp3A96p3CNbvJO+JVfBZiMgseC2PXnrWu+g2uV3ZLEwe0eFgD5RMoyfwI/lxU0LpLB5ZG8gmeEt9OVAz1/wAKzbeX7PdxyrGsnlnLYPDoOCcfoavFFtZp444gGVw1vtXcfUEfUUFp+8UJ+CXyju7YGAWwP8ankmMXDsBIByBjr2FTXsqoDJFCSzggtj7pPVV/xqhCXWRTGmGX7zEDr7ZqTdaq7LcaXMgBIcRDGQzYDP2p7RmJjG7fvCcE+vvU1ihkmfbEx2jCuX+76k+pPSrDwqkzKrxK2ORGNwT8aTRUHrYihcy7UjRQic5ZcEn1qTa7MyxksQPvZz/9anpBbxgSAPgsQFf5iTjkjFKi75QNx5PQn7uegxUmq8iJt27a4ATP4k+5qxESIsD5WPU//WpBGoKgDnHHvU0a/MAhDHoT2p2KvoVnjkTy1Bzjqo6c+tSPGcqScsOrdvwqRo13AkEtnn39TT5mMe0KnzDoM1Nh3E2iIAEKWI4Gf1NKke3B/wBY5H3fSmjeGILjdgHp0pRMTIUwMHovTPuaLjsyY/JH5SbU/vSkcn2HpVV9kakKCQx2gY+8fU98VZMuwYc73PJJ6LUUiSsw2EecePZBTuCXcrZuA0ka5xj58HAx6Z9Kpo2ZNvQDv6GrxLBfLyXUn5gO5PY1E8Rh3M/Tqqj1Hr7CkzRJDwp2qufmds7gcDb6kUjqqsVyC3UgdqiTGxtzIQT97HJPoKTBUtIu48457UEKmPMe3cJMtnqxqnKuDjBIH5CtTCCFdpkd2UMzdAp9Md/rVPzvKJ2gHb0XGeaHpuaQjcSC3OwTbQ3oDQIxggOFBJP3ec+vvUwkCBdvUjvSH958vDdwfShkyg2RQzIwwCdg6Erj8amjHmDKYG3kk4x+dVZmUSMAwD9GAGAaaqybM7sxjB2+hpX7iVC6uXlXdEcZweoHf8O9RouTnuB0IzTLedVlAclm7dsVdkWMjfjI+nJqk7nPKlyuxWMRkfDARr/eUUFFID7BuIGCOMY71ajQkAK3Ay2CMEUx4cPnJ2k5wBjNBmldiQr8yqGCgk/M3ABpxG9WIAGRtNIwLRnJwRwBmkIG0JyeOvpSNORMJUG1dpCg9iM4oX7wBBKj7rY61GWjRyAxPepd6schSV457ihMTpNIa4UOQSQxHGB1FNdPmwQMHkH2qd1LFApbpgk1I0RCADGV7nvTMnHuUT9/+8BzTJYyzAnHSr8UUaS+ZuYSBshe1NEG1WHXPIHtUhYrLDxwQB2zRVtAm0bmUH0Y0UXQchnJ80hEq4dQdvPJ+hpuzIO7e8cifJ2GD976e31osSkcYNwwYjLAHOBz3xQ294v3RxIGIjI4C4PT8RWqZm1roUpI5BIRFjzUwwbgB+wI/qKl8wTWSsmWmh+Qgddme/0PH5VacQzwZQE+SCUY/e3d+Pb0qnKjeeLmz4nVcOhbmQHgjHc471ZnJOKuuhehcSpHbB0D4J4H3D1BJ7k+npWfexzRyiEjawBYjoTk9SPX+lSwEQrugy7SAk5GOh5AHqPQ/hU8sS3cPniRjIcCWRhyw7fjUyTN6c4t3IrGQghIctIvAVTgA45YntWoI0jgEcLKynrjAaVj6+g9B+JrA2TwM0UZ2Rv99gRlhngVuWbWzRgeWzsv+qj6KD6n+tJGz01QMjJKgYssgHUEEgDp/wDqFPZWWMISFnc8/Lzt9Se1PDqFLNGXmYfeGB34AHallj3AtM4LStjGevsPQe9KxUZX0K5I3FIDu/vsORUsBJO0HqeTjH4Cho2OMEIoG3GevsKVM4wikDO0EdzS1NOhMxCHKrljySOi08jMYCMGY9WNMcMCyAgDofmA71Jbx54PTuSPSgLEKRlnCDaWzltzZH50OwDkRruGeSejH0zTZ5FRmSIkD7u4dfwp+3Jjig3e4z/nj3pFpW1GNvLMxw0pOMEcD/8AVT1YbeSfMbkVHHcbBgctnkn0/wA96sNADGwYEMxB39gPb3oSGytJKASi4eQn7w52/QetRSQCfCswR8YJzyPp704KEbKDn7qcdB3JqYxoSoizntznJ96Ny7W2Kcq7X2wqCoGC2On/ANeonQHAjJ+XqM8VfugVAVF/LgE1FjsR94bsH196GiovS5XLu2eGJ6E54/ColjHRSQw54q4FDEYyoA9MUiRpDkuV3N93NJotO2xXkkwoEcWGAIyeppsJdoGCrtVep6Z/xq+0MLlTNgFkAVFPJPrVmOKMyDfjATKqR8uR6+5osDatsYvllTvxyfWmBW3FS+PM4OB+la12gEiM6MzsDgDqCemO1JHCsTebMoEjcALjPPT8PWlYaZTgjS1uVl3OZlBwMdD61alu9qbpHDyORw2c/UdqsRWq/fRUbY2Sp5DYq5a6U1y0r3JZXAHMg3Y/Af5FUl2MpNPWRQgmjcZkYgnsOMVMUeSRdrrn1HNbMnh61Fqm9kdyxRfLflT15Hc/pWfDaSxRlSVJHBYcjPYcdKavszlajfQpEPHIxaLcPTpUMwDF9w25OeOM1rAy7QJMOwGMYwy1FPAwhVy6hs8YGcetIqDsY7W+6Te2RyQMDv2q5BACRkjGOeO9SKjCR4yQ3Od3TNOX5pQM4UHqe1RsaVNQCbVxszJ0IxRtfG4/dHGKsKjIg3Ak4IV/881Czgx7JGyQ2QP50zBRuKkSsx3YRh9TmkMeFbOAwqaD5uWLMB14xzSkBnJICk9zyRQQ46lAsgJAUflRSPK29sIAM9AaKm5fIzOdsHhHJyc9sdmHtzUNvvikmdFUsWDpGw+UDpke/FTyTCaNJsMWcDI/vOowfzGDUYDfO5dsyYUcY4HatupzJXIYXSKXerOIiC209S3qPX8KfcpEHV13NPL0IP3W/uj1pZQjQkSJ+6B7foB7571UJMJO8PGpAyFOdvoRTNEmia1HnJMn3JSMAbuJSOo9j71YcmPDwcso2yQyLyg/2h3z61WhtpUmVnmUuSMDAyQehHsa0Ly084G5imeNySrAgZU+g9QfQ1SehjKFnoUZox9oDRBizLkZPQ9wB7e1JaXLwo6S7gmQSTwfbFW4Lu3jkKXEW1twCxg5Q467T1z7dR71FeW0pGXPmqCWCk8/n/Spa6o0jLpIspdIAjLueQ8DB7+vsP1pV3bPPZ9o7AnBP+FZdogkmAlGZ2yQHOOlbHl20TB43zKnIBTp69e9TuarfQgBjeZQVXzR8oCZOB6cVcEq7yY1KBOMk9/bFDBASIAA2Bjjp6n61Gz+XKEsghZfmdh2/PuaRa95lieAQKrXEmNx3hRg5PvSEzYIX5WP94/rmmQrtO8YlZh0/u/U1ckeNQS5DKcYULy309qopaFeJcjefL4HyqO3vVd3+YIrFQemB9+rbfJJg7On8P8ACPTFIFWWR/MVACPlLNgD2pWNE+5XhQOJVABK4+cZyMentmrETZljB+UkYODUTYTdnOzAA7b/AHp2duxQhGRwB2pFMnkRjH5aLsCd+4/+vVQzkMBEM8feH6k+9Pcu0bM7EAc89Px96j+4GkwMHg9txpFRQruCjdVA4Jz39qjj3kfeXC9+v5U5CmFbAOB0J/lUfm4cZUMQcBdvBouWkPluhDseJwcHOSMms55WdySw+Y8gelWJE3MgbnBJPHQfSgpF5gQkcdPTn3pPU2gkiW2JMbMV3NjgHGB61qR3Cw2SybA8o+6M4AOPvGs2KHO5dq7cZwBVh9qR7c7mJ4H90e1UiJRTYkMzSGR5TjJ+8ST+QFWIypJecyLDuB2ooJJx6VPb2plCggBF5A9KbLBFMdokeRh8qooI5PsOtBEmiEXF3K7As6PtwiDBIXHoO1a+jwPKhWVJVkKkja3J+tRabpqQnaUWEj/WO555PT/61azHBtRpgDIo+c3CEAv3C4ppMmck9ERodTFwxEREWNikoC2D09/xqKeK+fIEEKheqDAz+Ga0J57iwVZ4ZsOTgBAQPQj/AOtVf7f9njC3iyxl8t+7cf4ZNO5zavYymjlFwzq2cABmxnj05qvI5XOH47A1dmvrcuWlV3xyVLcmqsk0MiZ8lAM/LtGWAqWaxi+pTMW5t4BCDnFWU2f6xkAKnPHQionUxthAHVuepOf8KsIJY4tu0YznntSHJCNcAsWwT3x1qGWJWVGwyKScY7c1JDFLczrEkck8x6ADoPWlvIZYpWSaIIQRkE8fWptchWTsgEEiQR/MecnPqO2aR8IcHBHpT+HwpwUA7dMVCyDzAQQAO9Fhcrb1K0lvLI5ZIiynuBmirUQfZwWA/wBnOKKQ7M5uFdrNaOdoOGiPYEfz9PoakRnC/MNqg5znharI7n5ZGGzOUIGSp9vb1FWwhcB5Bgt949g3Yj61stjhWj1GKAzKWBxztB55qs9uGIDnBHJGelWIW272lOAnGMUixh9wjTIJ3sTwcUjZblizEUYk8yRRxhecheOg/OprNirsjn92inIPcf4jsapRBcbnBZcfIoODn/Cn7o2YKxB25wwyAn/1qpMlwuy7JaW/EgiUxg4jBYnOf6/1qrPBNDIqR7rlc5kR+GU/7Leoq5bTBHSMIsaAbUJOSvHUDvU6K1pC5XcXkG0P6+pFP0JlG/xGTJBHLD5kWHR84JAD5685qGynVsh5HTy8ldxByT7fpW1GieTsuCOwGWC7QB6jn6AVVls9u54UWfcfuABWQep7H9Klq446aSEhSZow2IxBnlgxyT9KlCS4zIvBywGQMe5qCExLEseJInzzngfXnsPTNXtksmY0kBReXOMbvTP+FCRqn2IbZRgq6YTblQOrEHv7VJPIJJgZflfqB3FPLCIBV4VeDJjO5z2HtTJYkRm8hmfA5OOuaZqhqsWlyMdyxHf0+tSRRebA7AKUTggkDNNK/N5Yxv6Fuu73pkkoGGjPLdV/rmpLsyWR1IVQEY8FsjOKem5cM5LYGFXuKiZg1woX7gHLkYxSQkOkpHABwD3/AP10X1DoSSuGByVKnr6VCPKdQGAZl5x0pwQrtO37vzDnvimxoWQqAR0GM/mRSLjsMLRYYgpjsBnJ+lNwuEJBweCPelngAO0RjGeOe1CR7XO7OBwOOvvSNVaw90RgQ33iQCQO31qI2mJSdwwOw64ppd1+6DJk4DZxinhmaQCRgM8Y9PegpXXUfbRNJI5ztQ5CnpkfWpiiRuqjdIx5UgcUMpjQIxx329SB2qaNyiM7Y5GSMdO3FCE5PcfdSPLbqgk2xIQAgyBk9/rV+0k+wxElWikiHLsQM59Pf2rPE0Vxtjw6ISDkYzxStJHAB52xkc8Mw5OO31qrkWvpY1bWQT3DXU9w0eTwzZwfUcDJOOn1q7E4uTLHZs0qlTl5XMat/sgDn8B3qtamS4nSK2tflZfl38An1IFXJ7URRslzeQCZBkhGwAT39/wpmMrEcNhFYsSxmMx4ZS2AD/nt+tU2+ymcCZXXJw2w4z7AnpWj5kSxJHCtwUfB80jYfqM8mlnaCENviWKHflZJGJx7Y+vekRrcx3shdHbCAgXJRXOCT35qlFD5TbFPIP3o3znPrW1dxWslw9wys4yMhQR+APpVRHtssY2BctgqeSo7Zx/M0jZN2sQiNBtx8wbgkHoRUi26rnIIB6YqOaWONH3AopPynHQVYgAVjFBOJMjIkALAjHQZoE1fUrveG0VfJGTn5nHHHpVN7mXeXZU2HOM9RVue3eEFSoBB2YY56e1Zbq28KvysWwF7Gky4U0yWG5LNjblDyeOn096tHZINqMpwMZHUVSSNN7GTcM5HHrV2KLYwWI9eTmoCSQ8EAAJIoXsCDRViNWVcdOe5ooszOxyaHD5+Uqeu4Dj6UGUgD5chiQVx1FMlbaAsZJVj0P8AKkjJ2qThmPIUe3StUzzuVNalkhWVlI3ADv6ev1pLSOOZ/wB7lUGTgHlvamoPNkWM/JIT+7k/ut6N/sn9OtI7yKyLyhHUgfdYcYzTuON1oWLjbGvmK2ZCuCwHCj0+tV0hZp1cDG0EknkAfSriyxAJlMeZjAZtxPvTmV0yLg7ATwvr6fWhmkdCKDbtVnXkjKDvz/npUsErLH+/wSxzkcn6CmGEl4ySQy5JzyfrU7eUgDD/AFpG1R3I70IejEWKRphvXYDgAgdPf0qe3LJG38I6KvViPr0A+tVvOkcYeNihPJPX8+1St5jzKyhgi+hzn/PvQPyYtyS0eGxEDzyM49OveluYwoyVlWVsYQnn64NRuQWLTHzJYzlUHIDHt74HenTwGQ5O5bhxlS5JKqO/1NJMFYrnzWZvMcT3DZ2sykbfoatBHjgDzzRhS23Cj5ulQxiVmVDzxgHn5j7e1WLXa5kkYgyrjau3qMdQO31qtjZEFyghzsyI1Hy8csfQe31pkQMoyihExgnGM+3NWZXhe2XczSMASWPT/PtVWWMKsZG9Wx8uBz69KhmsdrDrmLO0sRlBkqf5Z9aYrMkasQFA+6OlSRAhCCSEQHvk59qlL5XzJDw3zIB24oDyK6uzykRkHIxuI4BH8qlQSSNgZd+mOrEVDESCIpFCluTj17VYjjIG8ZIUdfSgrYSGRmyjqd3IyaR4iqHOCM9/SqxmkV3AZQD68/nU7zhwvDbiOvb60i2n0B1KR7kGPQ5/WmxKWIMh4x1HWqskm6blmEYwcf8A1qsHAiUY2gjcPpQO1iF0cT73y6sPrVmSTbEigkljnA6/iaqszPIvlPxwNuO1XIwFYbl5HBOOAfQ0Ip+ZHbh1lLSKwjH8KtjP/wBatGzsS1z5szodx8xQ2CAPQD+neqsqiVQVOFU8gnvSuZIzIVZYggHPc56fnTJd2Xry+mwtrZXDojE71PRcGtHTxLDFCvlOyyHAdl2bj3/AfrWDpyPv86OREVG+Zwe/rzXR23ia4jWNbdfJ2jG513ySew7D8O9Namc1ZWijTS2e4bzHmW3X3bc34jjFVZoYZI2jVCGOA3mP/F6Z7/hWNcajfy3W+5lxC+4KOAQCeh7fhV3T7v7VOEEKKFyAqdjjAxnp9TQZ8jWoycuyk4VUxtDN8qlenT+tURbTRM7RqChHEi8ZHqB1rRvNPlQj+0rqIBgQqn55HOegx04/Cq1wkFrbr9nFxNEJAmQNu31U4pGkfIqMJnjVJJTIf7u3hh7VJawM+XYDd02jjdiovMXa8QkZEkbhFOeT+FMBmSXy4HkwvGCeeKRbTaLkpcSBbdwJOufUfU1m6np621yiM6ysRuZgejZ5H/160QFYbZDuZ8nsAAB0HpVd4xK7NMdyEDy22nkjryfSpkOMuVXZCEMbFmYMrdcVbt2RopM4VsjaQOTVS0kwrhsZHAUdasySMkm6KJ92e54+lK5L95XLCjaoAO4djuopPNj6lDk+hopEWOPD7C2B04OelJFKeSpyBwCeKcwyvyqBgY+tV/LPOxufT0rQ89K5K0rMowMnnPt71Ijmdf3jEzYx/vgfzI/Wq0JAcIVJJ4qYMpkVYxzkEdsfjTRpYnEYKeYismVHHXPrVlHgYoX428gjqx7D6VCVedC6n516jqG9wKsWqwgRhgARyWccD/E1XUFoiZ08pFILl27AcY96hErlwShQcKDjmrCyCJi5DA9kHOB/SnHDbRJGqiM5PqfehoIlZ7glikS7I0xucDPT68U6KVgrAySYkz90gcdzUFxcmeRiUHkk84GPpUg8plAUh2jG1Vx070rl8uhP9i8x02Fk+XdtPRR7+3erkrWlsqpmWUkbUP3i/HJ/z6VT81opGeQs7NwCnQnt9ce9RPLJPdqCNuOc78tnvk9vwovbYUY33LDyO5UqAUUZOOMD0/Gm3Bdt/lFd2MPJnAA9B7Uy4lVIT5ZLK2ccenbHYVWctJGqKSB13dKZrFF3fBHtEQZsdSOOfXHelUzmdpZPlIxt7kf59KghcW6EuSRjCluq04M0yK4xGD0zxmkUSkBkVWc7e5XA9+lO8oEkySIny7lyfvc4wKYsirufaFQfKD3JqGYrv8xhhm4B74pFRQhh/eMsa4XON3ZvpVmAZRI1JIU4y3qKi3Hyzs+VWPB64ohB2gh/ujkE9aBsjvNhZgikt6Y4H41CMAEMxB25GeasRtulcnCnoADyKGiVlUEDK9PegpO2hVtGZoyxdid33T6e1STv565JLFR8oPIA/pTyiKTHtUgYIJ/lTZYSimPgB/TmlY05k3cjRzndKUwQDhRgccVbhYvC0SgAFt24cn86rPCIFEZ/eAjLe3tUls5CCNWG5uigdPShaA9diViYwFHy4+6DyCajK3J/ekbgeFAGQf8A9VKwKuoznB5XsOf61es5EllOVGBkDOSP/wBdAbK446cRM8LKFkRQzDOcd8cd/atDT2SP7MboyeQJcsBKqs5HT8M1FFeJBKkkUYZV7Sk/Me5INTloI2iaNoooGyXKIxb3x9ecYqkZNtqzL2pyi+mlt4tMeH5QQSwKtntjt+NT29kbKKPeW+1sMRIcYz3OTyBS2VxLNp8yWNsVibDNPckKVIHHH+cVTjjvrm5d57p5pkO0SICQFx0BHUmmZLXTYL+FtW5v5lWQN8zw/wAXY8/4VXv7OyggitbVsLH8xd5DlmPXjP5DrV9CVX98yws2VVX4cDPJUdj+tRTae8qxs8UEcUZLKudxHcnGevuaVi4726GYtrbwuR5pE+0EDpj1JHr7UWaRs/ksjozqfmXjBz0JqGSeYpHEUfaTuV2UZxnHbsTz61dZEgjZfNHmSfLk9/f8ak3s0Ry2kMse4wnCsRndkClWWS9bDkJHb4G5E6gdlz0+veqt272paFNzybuQhyOnP40hu2jURyQ7ScYG4nH/ANek2CjdXFHlreuFXensMbvbP9amikQlpGACtyAOgNVDOcBHLeaDx8uRUrBWB2qOx2g9T61KQpQsiV0Z2LBsA84BxRUrq7tkEfiaKLGRxsrMELgHjqR0qAOEYhQSW4OecUpVlDAks36UjxOTvBK5GRVo4I2tZktsVSQAD738eegJ5x7+9MmAM6qWBHJ39iPaojC7MqAkkqTtX27/AP1qVGLqNxHYdMZPrTLS6plsSMu2RCA6fdPQirVpMWKuwA2jC7SB9apIy7t64z0IBzmrBjCNuUt2ABPRh3p3KW1i+shZQoTaFHJA6nPan+S2xlmfbwMjqQPp2qvZTMJZdoJDf8tC2CvqBU1w4lTyvNKKW4ZRkt6j6e9MVrMqwRCYhS5EQPNTyR/Z5Ntv+7U8dfmPvQy+XGYbfcQgznpz9PapLJDFEHJ3Sd5HPyg+n19qRblckWMRocgOzEYyeAO3/wBeq3nNH5ieaq7hlipztXPc09pHdsfK7scDcO1RzBUctJg88fLwCPWgaQ9o1t/9bH5SD5gXOHf29qVmaIljGSwA2L/Cgp0SLOVl3OFB+8V/PHqaarPLO22OJEXABJ5bPc0MpIRUQ7QxLO5xg96llKFmiOAyDBwPTtTokKjlvkY/NtXHvSTx+XKqyhWOMkL37jNA1uQxjz1Z2ChEyM+vp+JqLy90pxkswx14FOcyM67ANoJAGMc/1FW9u2Eqw5b8/wA/SpNL2KphYYCjbGAMnH3vqaRY3Ifci4JxknHPtVxiHUMAATwMt0xVOV90LxKwWPOMA5xTGm2NRhBLhowzfdYFc0+ad5X3MACRjai4Aq7ZBL+zAmZIbmAbVZj/AKwdtxqg8ZEhXOdpJ45/H3pBGzeu4nzNIgjA2jqPU08yDl1OWUYJA6e9UnmZJcFePanIXdcqMKeGBPWlc25Sw1wSezN+eafBtMwJYITyxIyR9B2rPWBl3b2AB59T+FW7aZQCckSMAoLHrincbilsaMe6xlYrtfcNpHXg+vvTpfJUK43pLnlM4qC3MrlyzFWBzubnn1qcQiAb9zSs5wc9j/X2FCJ2LVum+VVmkRXXrtXdj/E/pWjaW00TGSQIuGznJDbe3HTP+NYlnBcpcM0bsDxnHXntWpcDzfMfzCsiriNU4I9WJ7Y/WmmZzWuhp3uq4EUKRplSSoYlvmPc+uO9VLeWYGQtcOGzkBeCPcDsO/NWbBZY4pYma2jdo/nuZlJkC4zhc+vrWXGYppPOMgG5SWdwGz7gdxTISXQbcLFLfvO0rSSIch3JYe56dKsSJFOwMYVg6qMfd3fh1zVQXElgyzw5dpBjEg4+p7n8aswW8d3Ks8sphG4s7s3XtwOtIvzJ4IhBbXH2pXfcwbEakAkcDJ6EdelQtCZDLPcQrGN3yDG1enYflVvWJr1rMhZVUo4VSo2qo6iqEsj3duq5kj2kKSe5/ixQVFNq5HdSTRhiyoOylhzx3pszNKytsEaiMksB949zVuREllEi7RFAdvXOT+NU584xvBkYkqSahlLyIoyYnDLjhdoVjnd7/hTXkWAIJGwXbHTNEY+VkZyTjJbHTPapBGjRbjwucqWOSR71IpD3u2z9wcf7QFFAjJGRs56k9TRSM7I5F3KvjGPWm5YgZIwcgZ6/Wp3AUEAAj171XmyIyUbBI/StTzY6jdgZtx+Yk8tk/N705S6sGAPXGcURsFAz6frSZLk5+6OBk0GqRKICUPG1RxjP609VZWwCOM7iTwRSwjEaADPqcVIqr13BQO5PUUyk+pKCVjQFi7DJ8vGB9T/9erMRdYo8bcuOMdh9fX6VAiyfeVFCEZYn096nZ3DkFiJXI2qe3+HFNCepKIEtIWy2Gz8w/iJ6/lTw2VVnjKqeMEZ6c5+lUr5HjmibcSFXqB+tX7STzhm7lKRFRvV+S59B7UNlJaXHqHizPuKBcPuP8WfTvUJeR0cSJHsZcAN/OmTvcTXYSIFQuSuew/lnFJdOVkiBXnjp2pFpCjny413sx+6TwFx7d6HVo2kKtkEjJA5P/wBf2oBCA7Nrybd2VPPuasW8m6KMuqI69OOn1pj2IGBV12hWjJzj+JvrSEP/ABHc5JJI5IqWNyzuCMwg5ZgMknvinSS+VHGSDGZOIuOduaQ1crxELCAo244aRjnI9MVNK+UChiO31FQOwjRERtwIwzY5OabkrMQc9MZIwfoBSNFG+opjYTRsoYHsvTOO9LNgAIFUk8nbxipFLZBQOwbIx9aRYwv7xAS3UjqKLDvfchIKSgL1HOM/4VIyK+6RSN+OQOM89BRDIEBKbRjsw5OO1VJbkFyAec56YxRexok2SNDuAkYkDPBppODuCgAH/JqSORhFIOpPBHtUKW6bVZ2xzjg0ND23Jt2+UqwJUA4yeSaYkS+aWA+megqVlEafMS2fu46mnQCRyr7QSTjJ4x/9eheY/MsWyM8ZQnC9eOmamjiKzeSjbgf4j0z7VBE5jZWI+X6frVmO53xqShCqcjP3ge9MlplecSoDIHIbJAwcHHsa2ILqCWxiSRWEa8BlTncR3Pf61lpD5qs8cgyTu2sc59s1YtygjjW/utp/gGM4HsBQDszRuAsiJsdw4wuGGfl9z3zTFePerWkK7o0yHkTc2fQjoPpUNvNHazuiSStNjDMueF+tJI8cRlltyynOWcv8q59z1P0oIS6EzvcaeqTXTeZPJyMoG696SCRA3+plkucbhvHAPr9BVKS4MriT97KvILHlguMcA0W87IbhYo9kjgbCDgfU5P1pXHyt7lm6j84CeeYzSk8RhyMY7mo3BhgDSptlXBVAPujsfrVuyuPIWOGxgkeRgQ82Oc98eg9qRhLEPtFwVHmHCs/XjgkD/Ggak9hrwCNhC5k8tAJHC8kBu/1qncMss6C3OScqgC5wBxz/ADNTl5WhMdsxSFz88hPUetR7o1dxASQPlLjjj8etSxrTUryqYd53Z3H5eaU7iq5GABgE9hSlWDDjdx1IoTJwD0XipdiZMMEdTz70U45PRgKKky5jmXUC2JGGeQZAz90A1CFDsVboo64649KlPIztAVBjj0qPzDhh0z1FbHnRuRzL8mF7nOevHalhAwMgnHWlkZdqqOp4OPaoW+T5x070G0btE6FiSFJDDPGKlgIlI3LtwfunjNVs/NlAQnGCeoq0hUSgrkBh6UGq0RZEZchpGIGcfewKuxLCoIDsSBgA4/PNZKsQ6Bm6njJ6Vs6c1u8plltzcQohGN+3J74qkTLQaT5iMgKIFUfOx649KhuYXe1UpJgEbgzH5dvXr74q25ihumPlIR1ACkce/fgVFKwETPKFNuT8qtwPocfyoYo3TuiBbljFFsQO5XaMthT2GRUCmQqYm2tI7YZz0z9fSrYhZ2QQwLtkAZOCQ30qwclWeQDdu8tQPusfQY/nSsapkVratGwBxJghmKZ59qmEJWZ2KsBJkqo64680yBnhm/eb96dcHAb/AD+lTNMC5kUAMD0PIPsAaYN3ZWLyoEHIboMNjJHp+lErxSLJJtLSZABY/d9cD0pjzp5z5Vg4Hyso5z/QCk8kqCZOGb7xHU/jUmqSK7ztIohjYlfRT6VZlAKnftJcdc8f400rGo4wI8857mpVUyZGQRjr0H4UWKciNS4jPkcA4BIPJHp9KdChUbncPzkKM4P1p3l71UBCi+pP+cU4jZGZM/MeAvSgPQiIaRJNp2KOcE4z9KzzbtFNkngevUD61oOuYy0nJ7Z6r9PeqcJIkYkfOeCfWg1jdJilgLlVQHngkHgfjVmMc9ue5HBAqvMwXAcqnGMjuKkF3sjVBs2noxGWUemaLg03ZoZJIrEJvYAchAfvH09jUsSssZYZwDyDniqqoWmckfKfunvx1rRgPmoSzklzyfX60k9TR6IYS4jK7VKkg5Lcq3Y0qSvG4V0dmHBJ7UFtuV2qVIxz3xSxECVVYbj7/wAqYhLmRAsnzlHbGFxhR+P+Fa+lWcE1s0j38ayogVR5YJJ+v+TWFNmRjIG3Rk9SMfStOyuS9vsNuuR1YqOR6L3/ABovqTP4dDabEXl4tIctgB2JDMBxkjPJqtatIs5zbIsUZ+VWX5W+maorNPFcLNGuxgRhmyePb0NSI08lwftFwIYmBUnbkt7hc/rTbM1CyL9zLdSzKlrbwDClttvHjcO5J6/jwKrSaRBBIWklEsjLnyoQVA9dxJpfsiwR+Y052MQCTJl3+gFWPsiwFQ+JXlAfyIgSyD0Y9jSC9thI5kVdkUy71+8qKWHTAGe9VpV3Ru9xH5ecYEhy2PUD8O+KupdiCSWKOBEkbGQh3Mp+pqpeo5uGNzlSDuYA9R2H/wBehsS0ZUmMsihSNseAAo7D3pyxImOfmAxt6VJHuZlbaAvTbShMzFVO4j8hUNg5DCuCMDA6CnttC4UdepNPbbtwBk9CaYFyeRn+EACpMXIiLMpxG3y+5oqUwsTwgKjgYNFFjO5yTnaOc7fQDmopSiyN5allHTPf1qZ2xGd2c46HvUHllY9wAZieR7Vqci7kKqTIAc5B7U98cgDOeCfSmbyQVA545/lT4/vkuckDsKDoiNhLLvLDAHTircbFgDjIC8k96h2sGySQp4FWYVIh+UqCpx9aCm7iSKyoyhFJ4bceDnFXtM8zyTGJI4snO4n5ueuKr3C5jVlx15HY0yFJJZSflUH+Edce3tTFa61L7uyEYdmDfxemOMD2qV4C3B8sISCS5wu7vkVTimEEpiVN5bHzdcVbvzLMg8hh8rZ3kdf8e9A7NNE7tjzNrSGGPlmLbck9AB2HPSq8kqpE0kih5Q2AmcbB+H8qgffM+C04RvvDblWYdeeKtsLe0tjuTc7YOWAwPp7UXNFFIkIjZQQu7gMfnxzUTSrJOGUKFUbWbp+AHr70zz0jg3lWaQHHAwBnsP8AGh4pGQeW42n+FeMeo96LjStuRlImk/dlmKjoe34+tML+dLl2Jfd/F0pW88NthRVDHG0HjFSRr9n3yMqttzg46CkaKw1m2uplAwDkrjGamRjIHaMAhfmJJwAPpUCtJK0b/Jwd2SP88UXMqRArgnPO3r+NK4+W+g9ZtpAJGOeB1p8LNLmTkL2z3qpHNmRWYkkD7vGKe8hXaT948jA/Si5fLqWJJF2shB29Pm4qOLiUmMjA56cYqB3kdTvUkA54PANSWrLtCsTnHJxyaLlWsht5aGTBwdrdAp6Cowm0BTtBTAy3IFWyoKkJ169f5VFGoQ/Lw3XnoDRbW41J2sRRkb9ki4HGCo/WrFtGvmHOSBxgVFDwcyE9evUAf1qa3bzVbecL69hQhydhGiRFwVYgnselPWBGi3SAyHvGeA3tn+tSSyxptUHcDy3p06A+tMScM5Vfk453H9KYrtolhs1EJaAmVDyQfvL7Ef1FS6cszSHykJOcgrwAPxpkPzXDRwYyAc4bGfx7fSrCzTKUAlDMF6KM4HoaEJt21JVuLpgyLjLAgqTwB71JEsLsu8xucgEKCB+nJ57UWtrcJMA4JA+YKPvflzjrWgEVImU+XHj+LGSTQzOUktEVVCR7nAcSfdMpHHrwO30qGJIpZJyGkjTGAXcDOevPv6VanjgaU7VNwcFiXGcD1wOBUYUGXdFGss3Q/wB1ffHSpvYV7IbEpCOIYzFEcDcx/UepqNyoZggZ+MKz/wCFT3Ku2DcyA7eMKclvpUCKF3lm+dvxAFJsi/UagYnHGTzxQ0eDk8ckcUgdF4znnPH9KFYsCSTjPQVDZMpDj8wwDgZwPenKj7WwrjLYHGFbj1NNRmFwpXGD8pC9KWUONwVQxxuGT9wDtQjNjgjSZMkwhfOCmcUUsUMjIC0cKnoQx5oqrGZxj5wSwwRSqqi3cODubG0e/rT5sMPmbtUK4R/7yjO3nFaGCdyEx5z2J4NPUbWGBuOck/Qd6Co3g5JB5zihnURtnuR07UGqYvJXOeccDHSrMaGTKxld39w9vU5qrGXWQ98fNgelWY33o2TtJx2/Sg0WgRJhJAp3c456H605FJcE4LEnoOPwp8St5ZLjCg8+lTRQqrysxGQNy84OO3FFiubuIsuHbywxZcZJH+c1Jl3U5YhzyWzk9egFU590j8MwYnn3pxADM2446BmNItI0FvyiETKZlTG1STg/gOp9qLmV5jEFRRP0J7/l/Wqm6XarNgEAAcdv8KuLcpbMIbcRs4JPm7ck5qrjsV2uGRdsx3qeT8udp7Y/z3qzDKzRlpyFccYHO32//VVSZpZJ2LybyeuRgD2AFaVoqRoAwVnI4z296SY56IaixRRbzt8x+jA/dH0qtJGsssStkRscKW7e9WPsyeYSxPA3ZFMYiWQpKAFGO2KAi7EMjN5jLF/qgM8g8/X0ppizFl87ugx0FW5FjfAUsP7wA4qCVgpbBBxySDgr9KRpF32Kq2/lsFUjphic1amhjSJg4MpxhW7j8KrQTec+3G1F4DY5/GpXd3cqFJXG5sEKMe1CLknfUgQhMhlA9BVhTtQDdimGNVYlWZkHTj9acqYX5yxGOMd6ZVyN5Rn92SxHX2NRz3W4qijk5+Yc1KY1IJyT7Yxj/wCvUcFvkllUBfTrU6lrl6iQsZSeCACMbs1aToVGOenOaV9yDkhkHJPSmhVkQhyFPbAJzTSsS3cjmC4UHlhkDByCant4OhlCgucDnH459M1WCssmNoLD1X+VX418x1WZ2VccE8Y9wO1F7jbshJY2DAoI3KnaWHJH5cVds47kTq0EKKxG5QQPmA9R0pYRv+SKYSN97djmoxbDed0+QWOQOf8A9VMi90aMkswhbcoGOgDADn0FJBcRt99zK+B+7VScH8KhTfFDtFuxXszckg1OpeMMVMcOOQN2WOfccVLMrIknvWkkjtmkaGBeqxJkjiozM2dpURr029Sfw/rUJYBsqAGJz5YXGB7nqaVVVHdsg7e7dRnuB/jUkuwyXaceYdp/ugVErBx8p2fhn8PepwEOCECqfXkn/Gjy1VDkMGI6DGce5oIbsQ7AuGJ5HY1IGAXcwGO5Hb6Cmq27csWMjuTwB+NPXYzqI1Bz/EB19TntUkskWKIx4ZwBx8i/zJp3lQKWZpfIkwBgnqKbJAgSRC/lKTzIRjP09akjezdQrK8mPlZvp3B9c9qpEPYaLaQklZZBk9sHNFBaKUBsyZxjlsfpRTuibs4x+UPv8341T378jacjv71byCpAJKg5qJlAfBBz1GKuxzoSMgn5SQfelf8ADB5IqVEBBPAPtULbvMIbAPbHpTNE7iAMhIJ5608YLoAfmz+vpSkBnCI2Ax6n86TYRwh3L1HbB7mkaotxZUkSH7vbOefp3pjNu3Puyo45zmm2z7jhj82Dggd6I9om2EsXC4OBjb7+/wBaCktRzMmQFJOTk9MU7O+RCuM9NhPJ/GlKELtUDABx71JbNGDgxnLc9egpFp9ixGCinDFgg4YDH4DNP+zqqEFuT1HTApkkpCAcqOAvv9e1SLGq+WmSXfjDdSPX2pgrixKFILBQyjgAHP1H/wBepNzxs5kCEMSRk5OPXNQFTFt2sQwb5iRnb7e9SFd8bOm9s5yABnH9KEVYVTuOQD6l24/SmyjazYZGYgFW/oBVfzpSGwmW7Kpwv4nvUQlLOxlGwDnKtgH2FK5SVi4WGcN0zjOeaY0BOVJHPr2/GkV9nIX/AHSR1/xqRz5jnJUIPmPOCT6UFq5WZlTaIkbB6k96UgSA8gDpwOBT12M53g4yBtFRM6vwqpvDfMD39uKLGgyWRzsRd+0YyB0zVkBxzIuwucqAen5VGqLIxO0e3UDP0p+4JkNwFGNwHJHoKAvfQkUsqlCqlScjjOPxpSEUlQyKAOg4z9KZGxEbbQUbsCM1PtSQ5BZjgZBOCPpT3DYqygEfM4ZMZ4/z1pR5iEBVyAOD1NSC3UhvldiMY9M55zUrhwwzjAPXpQO6KglcMC5PzZ+pq4C8iKxQAY4yaZ9nMx/h2j81FSRRIwCFwG7EHr+NINCSGJQAGIXH3drZz+FTwROFLBlaMdBg5JP8z7VQkAedxEJGbpwO/pmrscEsUe1o3i3ZJJbnpzmknqTOSsSyTXEjMrsdgGFycYPv/hTCs+w+dJ3yu3IwPWo4UVNxjfb/AHicnJ9KvRxOwSOYrszkE8duOeuPahsy5kkRRqAN0bFck5d+Gb6+1TIm5A7FXGQASf6dTU7iGMZjTKucBpOre+P6VXEga4BQsCP4jwfwHb8KkyciWXC7iu7ngs3UgdsdhTHCLnLqCOgxnk/1p7gcxK28/wCz198mm+WC6sWG88Bhzge3v70iLkZhAOZSvzcHcOoqdPLmyBCViP3QxwGNSwxjlo1G8n5ndgaWCRmkkQrsiAIL5xjNMhsrtHMIioUTo5woY7to9qkjVY8RCVIgCSUwPT+KnPFJAU2OY4QDxnr6c1HKyfbxGLcqMAjGSW46/SgOboVZGt3YsSTu5+VOKKGnEbFZFt1OeAfSigOY5KJd26JcN3zjHSmgHdxgAcA06ImLLFgTggAjtSKVOD0z+lao5Ux6qR0wMdqrzxs4DIoBHvUqt8xZiQnTPXH0pVK+UQCd+eQKDSN0I6zCzzCF2N8rMyjIOeo71Ahwv3ieelWFPB3E57U1FWNmCck+opG0XbQWFO4ICsOh9KmRSZQDxj/PFRElFQZGMZIxkU61kLOG/DntSNOly40Y+QD6Go5GRGUhdwQYAPelL7k+8QSdo45+tF1GxmRwVA2rj0wP602KG+o83KKzOzZyBxjI9sVZiKuuYx856k9R6VRkVHZVKkgnI5/nU8amJNqtsbOTjj9aWpo7W0LSrh1+XL92H8NRTeaGAjZljPqOPpmpd8kke0MFA5yen1z3NRzK7CPJO0gkDPJoHF9xqEBCSQQoIwe/09KiCiUiT5srxz0Wp0VljA3Yx9OP8+tI/kSQTct5igFUA4OTiixT3EmbyoWDEPznJ7e+aignZ9yiJSBgcrwMHrn8ac+JIvnACEDv3FMSPBULuwOQF/xpamqSSsNm+QbmkyB39yelMjXcfkIB6NgYNSSIG3vNvZ8/KM4C+59fpSwKYHCAYbgggZoW5XQs4WJfmAOB1Haq0rtI5EauWxk4GcCrYZt/P8R4Axz74pt1HmMeXK3ocLgGm9SIOz1KEW5U6cepb9fpViOQA/6xV3dQev5VJBbEwLI7oqvlOTtOMdfpVREDOxAO4DH1HY1OxtdSuXwoAKx7iOpbPQ1MgSTczOTk9Tyc+1Qw+YI8EnHcHAqaDKsBjEYPU9yKpGbJbmxECRmRxhhkIeoPbmpYIowQnlbvc1XBdTlvmwMDjipI5MMFZgMc+5+lFydbassk+VKFjbHoE6fnT4YRNOqvMTkEvv4UY/nTJrhDtGWGcfKAMnj9KdbYaPdHCWZTndI2efp3oMZNkkMcaMxmkJbJwqR8Y9amWR1yyr948SHnj2pshD8O0kjHv0Xj+lRB1kdnld3AB52/KvoABUGd7kzsWVwoz6uTnn0zSRRMjb5MRxHA3Hkke1MLBpQHDbv+eWP5+lTBpTPtfDlemOVUfU/ypWJuM2FCDHCxIPyR9AT6n1p7NvXbIV3sMEJ/L6U1ZQJJPJG9hy8rnp7D2qMyDbvhi80HIZsEL+H+Apk3uTs0KtEwYysoKosa/ID3/wD11M7St5gZYcAfKTyfrVAXQjKRK0iMcHAX9aiDxkbQ5cSglu56+vagGjWgiS/vYorp8hMudpySoBJOKiskM7XaLdSRzbGZAMYaIdQfTtUWnqr38DWkqxMVYF/7u0ZzVm4uIfsTtBfwnjayxWvlmQ+mfT9KaMpNp2KMaoEG6RSfdBx7c0VWudrODLIFOBgbQeKKCuY5KULzsUAe3QUxcjGMelOJ65ODxn3ptyQmzywcHAOT3rQ5kya3TzJ1Q4IIIGehOM0obDFpDvJ7sOT9ahZskN39KcAwiMpBZGOCeMig2iI8oJGBjBAwakJQq8gPQjK+tQXXKnHQnqOtRglipzt4BOPWkbxjdFrd5gJILDOFB/gHpUMLNGDsJHPSnxkjbu6n3pJDsnULgevpSNI66E7uco2cgjByKsSYaPknK8rjvUSLvUYbtnj0qwgZQSFAGOp7CgLixjDbRnceQe9OMO7HmMQyc/T8Kfjcu7O0jqc/1qcIpwRyR3NMG9SvDOgnAdygz945NH2pJHHylQq4VUHvn60lxbYm3ocKeeR3qwg2RgeWAB04/nS1LuirL+7c5ZsA559fpUyLuUxxMQGXOcYJ9qa0W10L7mQnnZwfw9qdGjCMlZMJyMsOtHUtWIoYoww8wrx/Dmp/LSNlZmz/ABBe34ioVB3bsjjqAMH6k0HzBIQVcY68Z49Km9jS1yfzAJACVJfru6D6CkzFlmQbzjGAePzqBwhYbpQozzgZJq1CqqhVSAG4A6DFO4noCZdMqB74qUhTb+YHYS9MD0oACISGCx92A7fShSJMFYyOvzGi5IQInl4YKxYY8xhVeUQpKoY7VLYbZz9cVPICjlZF+c9uxqt9neZvQDmhspJbtl1/sPlgo7uMcKB09OTUQ+UfM2fTPf24pFiZbcru2oOuP880wLvbahYbTk4GaL2EmWossM5QD06VLHEofeSzHHbj8PpSwLuB8xlXB4GOKn2qrBS2F/iY9B/jQYyqakYiKkeQiADGWxxn8etSOcuwb58HGP4AP6mpSwdWJV2QcByMKRTIsZ5+VR36496RjzA2wbXYmQdDuGF+gFQtcGRzGjDB4KqMkD+Qp/yD5omd26bsdfx/wpgVlLkgop67Dz/9akLmJDIfmTc4Zfvk9QPc/wBKkDPLEmxxGhOSxyAfwqOFSAwURqrEdTnAHrSPM9wr5QSbTxuyEPt707EOQ5g5L7U3RDk44yP65p0c0zGUKI0QHIUkgnt1qDdK0LfvQvPzknAI9AKinkidEkWRVOQBuOcD6etMVywYmeYljG23g7W5bj09BRI+I4gqNGcnAUdR3J9KpRbmlP2mYJv4yg/QYqePcJJEZSUAwcHt2qRykaek21xHOs1pbiWKPOVZ1AZsenXvVu6tSsEzNp1rGu0tlZOR68ZrnlklUFFwW7d6ZJbzyiJQSWXrsUsevOaq5k9WSzW6yyMxYJ6BfSik82NeGchh1yTnNFIvU5GXIwOg70rDIGOn8qRjmThcD3pxGR298VqcsWMODJx+dWIpQsoZQu5eMEdajUAAADJz1PrSFMk449aR0RaY0mMT7mjDx5xtz1/GnLGnlDYdzKRtz29RQIwV5GSKYGZcJyeOvWkbrXYmbbkDcODgDpn60YBIUdj1PIqBmA2ZG3J6kdant03l9rKMfcVuM+p+tLqax0VywpdCyhd0vYnj65p3nMAHKMdxIVR60xJGYOhPyOoyxzk06OMvNvx2xheOB6UJj06j8NM6bABnlien4D1qyreXnBLSEYO45qIkqRs+XHy+mfrT4EYRZfHJOD/UUDdmH2lgFVWAC/JgdD3p0FxIdwdx5YPTPFNt0yrQhuHwGLDgfjQNkU2xFVo+cZHLe9D1GktkWlzkYxuY8HGfy9Kbj59qp36DgCojcnauzruOVP3s/wBRU3nvMyxoNzDBwBkj2pXsNRY0R4YkkZpZEcRjzCT0wOc/Sp2V0i3KQAzYZSeVwMkn2+lESeYVeOclGIV3GMqPpSK5upUSAOC23OOQG4wamRFcKjqvy9+5qPeznZyzdOBgEetOjjkUghicfwqM5oLeu5MA/l4xsycYzxTvM3ZCkuU4yO/+FQEF1DYO8HAPerMMYJjEikrnJ2jBNBF7biKRKMZP4HPNP8kqjbQSc4+93p8iL5nyfI3cegp6IEXbuH880iW+o1InEeZGUDHQjNTRWsRRMRsSRjrx9aRNz7lJIK8j3pFbcxG5tpHUcAfWnczcmSSOi4VkVNowMD5iarDDMQFJPXLnn8ae4LkpGwOepC0JEY8qhJGPm9vqaVzJsmSGSQgN82OxOFX60jyKm5iisAdu5jwfp61GVYxkgZUjn2P9aiWXYpZzuYcBsdPYUEyaRLKdjBmOXIwM8BR9BSSh5MOQXVflJ7Z+gqufL25kIA6k5x+BPeoUnYMNpZuOVA4X0wPWmjNyL7XDbFXhlH3YweB69KR5pN+UjUgDAwf5VTMrsp3SYDcBVHAp5iUk7JfLAH3Wyc/4UEg8iySLCNqMDyOv5dqjmljW4L4Uvjj6+uKkHyeW21XXOQV6/iaicZ83MYyecn3pDuKZpcZWTn02YqJnmR3kByzEDg9QetTxbw2DhkHVmOf0p5AYjchLLyCvHP8AhTsJvUl02CO5u0if5VZN8jAZwFBJx74HStOC0jhst0NxdJPLC1xkNgBM8K3fkc1m6YjG7RIJ2iwGk3qM7AAST78VoXhe4W4+z3kzGa2S52yAKZFHVTjpx26U0iZPXcyWILEmNixOSfU0VGXU9D+bYopWNTmhwMk0pG18Dv3pQQeVx7+1MkDcYHy5yD7VszjW5JGQGCgZIOc0oAOGz0/WgDJ4IOKbhCrFlO7tiho1i0SISBg4IPOKSXG75V5PbsaWMbc8ZI9eOtSABmJDcdOBUtXNk9Sm6nC4zjPPpUqRsV4PQZx1H1xVgvk7ZABxkdh9ai+aMqykDHcUrHRGb2JYlZTknn1NTYbzAEztGO/X8agMrbe/zNnmpN8jFQvQcnPY+tIvUskoVGWw2fypiM7qcMM44GMVEzZTIOATzg8mnoshG8vg/wA6TZcVoWIwyyBVjOQA3Bznv+VQypLO7SKR8vzEg849aYiyCXL4I6rzyPpVmM4UvtVlHJB7fQUFbaorgNChJJbIyCRjP/1qktYpGDOi4wNxOOn1q35e4JvJ2HoAO/pT0MaB1BZWB4GOPxpNCc+hQnvJROrpIcq24u5AH4DvS7SYvmJA4+ULjP4VMIP3xZuWJ+9jkfSrEaqIwmGJzjpxS1ZrzJaIYgCEBzgAAAg1NGrRtuBwT0OaZsQnBG7ngHirMAUABQfM64xk/hTM2w2DPG4Nj+Ij86bhlUeufvd6sJGJCGKlQT3NKVjDsynGeg6lqTJ5iKOR5EMSoM5yTjkn61M+EC7V+YAhn6DPoKWNZWUmNQADjcf5Uj8vhfmbHIIzigzk9SthmB3OZNzDAx0/xFWvsxZMSsRtGQgPT6mmQoVcknbk/e61aijRlaONCzA7uuABUkSZAmwphEy69xwB/jT9gMeZD0P3TwM0si7FQu6FyeFA5z7e3vVe4cxRsMrgn7/3h7/WmZNkczlTlsse5LcH0qCVoMR9WkI5wOM+3sP51EZA7fe4H8Td/oKiadwcDBYgZ/2V/wAaaM5O4+clug4A2jjczH/61QxgqNoLburNnvTEOThXAx03etRfaDh4yeAeTjINMhMtp9zG7hucelPDr8y7wydyWwSKzWvnER2Nx0zt6iqUl1syZHB55BzQkNysbb3MQK4BXjBx3+tK90rAoemMgEdK5aTVUVm2kuOg4NUbvXJI0do4JDjluQOKtQYuZHYfbgG6AZ4JPP403+0FZsZ2Be/+Fcb/AGrdSY222QcY+cHiq8+q3ER+eBlVjxhqfJYqOp6JpF7I+pxR2c6xz5JQyfdzjkH2IzWrPePPazi3uNFiVIxHLJDI2QmenI4XJ7V5v4e1S7bVYBbWUlxI26PyiQA6kEEfl3rcvIDpNlfSRaJqMKmIpNPcTxMscRxkLtPJIGATVJBK19hupXdxb3skN0FEqHB/i+hB9KKwdZ1Rb6/eZbKZY9qpGof7qBQFBPc4HWiosu50RatqjbHySAkfL3HqKQqMk7sr7+lKwIJzznihV29CcH+daHmX6josL8vQD0FKQpQnq2fypiOQzZ7U8bTywO4jpSNUwOXGWOD0GelTK6eSoCEyg84wABioJGAy25aEk3g5B468VLNo6ofINskbSE7W5xjkimhiZOQ20527O3vSOWMiSuzMVHyk+npQjBCNuQw5GTmlc6o7DjIqsyKTuI56Z/8ArU8SkxhRwO5/xqq2dxYfKxycL0psb/Mu5FZQeVPQ+xqWzeMdCduCcMzE9OanhbKEO20rjaMZyaqHc0vyDYrE4Hp9PartptCgN1HdjSRpeyLTMFgAKbmYHcMY5p6B8ZQKSy/Ng/dPcU+EibBYgIPuhs9fXihEcybWJEfTI6VRk5dByKoZVwzE/wARqSDbI5bDE5JYnnFNmISLGQc45606Nt6MIx5eByx4yfapJuS7fLcHIbB5AGakmaWT5gDtRQAM8Lz0qESBVKqoOSAzZ/r6VMsvKlcsMcDHBoBX3EFttO9owFHUZyT7U+NwZGKxFRnA54H40mzzGyZPlznOf85qWLGz+8AO/c0h3HKxbqCc9TjipHUOVUgggcYGKjd/lUnlsYz2qQTFn+VQoxkNjt0oJfccxEeQQz8cKDimgPxtT5m6Kvb6mmNIA22M5PcntUoieOEPI7DeCcigkULtc+cM46t71M2Xy2SBjA9v/r1VCqWVfvADPzfzpYgwIV2Yrj5mJ6D0FIiSGFDGHweQR8x549/Sqd/KJTsJJGdxOMVdm2hegWNs4XsP6ms6cAruYH5jnaPQUzJ6lUxlAPlBJBbPpS+WIxnOc8/Wp8mNFL5BHb1pZgd8ZAZuMDOMCgllGNSxbgbSOx6ZNR+VGh43vjPBFXlheObCKFO05JOfrim/dTMbuQvBC8jFArGZcxJsKIpRguTyQT+FVxZwSB/MVt3HVs1buVIlEiRmPJ+8D/SleFxbfvQACevp9atSI5ShLp8BOSFTooCDoKpy6aGcBeT7Dr/+qtkupI+XkDHyY204xh1bpwD92nc0ikcx9kYEeWWVyOoHHWi5id4nDRhmJBJA6fhXQeSQw242le3HHpULQqZQY84UYBY/e9adzdJFTQJI7a4iuGaTYwaNljHzgOpUke4z0rSuYLdtJSR1vJJfsbaeIPIISfDEq27oNo555zVvw7bCPWLfYq7mVmDjGI+D8/PHHWrN9JfCynjl8RwXQCEGPe+5/bp1NNEyXvaHP6cmmx2iR36SmdPl3JyGA6Gik8u3ZV80qGA9SM0VPKbe75k4BAOSDjgU7p/DSDnPPXrSgjB9uM+lao8bYZKuCcfeNJk4yWJIHWnsuGVv8ikYBk6/NSZrFjIjvyCdo/Q+tTghptwXZgfdHeol7AkYUelSbCDuUcZ71LRupD2iQ27dQ+7IweAPeoY0wyqwHIzyasA5Rscs3H0qMOEcSEfMpGAf89KTRtCT2GhFMbA/LIDk+4pIo0ZQWVhEeQQOT70A/aJHM4C726Lxj6VIzOZUDAbAuwEZHH0qToTHpEAPM+YoThS3cU/y9zMUBAz94dcenNSRoxQnGFHT/aNWY9oQkhVDfNhaVhqdhkMJVAQxDH1/rVuNfkCO+cDHFIqMGbYwwP1FWI4xy67mYDJA6CnYyc77kU20v5aj5uO3P4VENx7kAdVB6fSp2JUbuc+tRxoCzbvnJOMAYxSaKUhJQrKgJB2c4H9TTIXDOwJ3DGdo6Z96kkgZE2lgCDnaB0psMW8fINmOTzyfrUs1i1YtxAsFYLknt39vpU24sQr469B0FQwyBFwDlxzwP0oRgcNyzctt9PakInVeWKDc3cmnKGjwyMNvIGRnFDAHG75SeiCow7KCABhei0Be4q/P9zCAnliOM07eAykPuXooHU0xgDgYZjnqehPt7U8KN5U8kDJxTuKWhPEMKQBkt6nNK+3eY5Qzrxn3PvRFj7sZAxyzf0FS5RvlwFTqGJ6mkYSZRlOJAcDcDnk8VQnZgWaMMXwQ2e2TwK0bhgjk7QwGc5OP1rMZsyuyjC/3sdTTM2xwVpBGFJI7k88Cnq5DlRuYk59sYpZd7IGOUyB8o/rUoRg4CEEKBhjx+NBKIpI3kRJGYqgyQoOfxNQbVVdsK8v0HrVh1BBG4v6jHcdzTYklQsSNoY9+cUg6EE67VDTAqin7y96pSjELHaRExzuI4Y+g/wAKvSxqYxI4J2nuKY67kHynywMAk0xaGcAflbbjZ3HanIjPg9mPQGpHjypZizhR0UetWreEEDcGGB0zSDYiEMitkcjHU84HrSlEGMg+aRwSMH61b2BQc43ZyAo4FRYSRtxUgDjBp3Gn3Lmi2czTLdwiCRASuyaYJk9MY9Oasappaixnf+zrCMqhYtFdksvuoziqdpp1zcZeKCSaLlcqmQGqd9OvEhLtZzhF+ZndcbRnvWiegm3e9zlhp80hLIIgpPGc8+9FbzBXYkxmTtu3UVGhv7efY54H5QadjgEkc/rTGwPlx25qFBtyOvp610o8yxafO0UyPKtgjg0ZJTa3PanrjPUYPHPakxxY1gQRyOenNSLINxWRjjttFMwQSQe3ORTMsCSeGHf1pM2hIliyxHGBnvTJ9pKgg+ufWmo5D8MPbPY1PhW2kgHnJzUs1jKz1D5dgPZugHXNLGjYJB3AnHPXNNaNghCsBnkYPBpyIsR3KzLn7vt61JvGWhYUMhZcEheSe9TxsqsC7DcG+6R2/lVASO7EnqeuP51bg3KAz4bPDc9KRdy+su51w3zc4UdKlWVvlG/5xnJBzn/61UoYsuBCCx5GM9T7U95MOVO35R/COv1oJcblmTarqc5B4Jz0qpBGIZGAJLHsT696BP8AMUGSuMlu9RfapkDtDH8r/Ic9TSbLjBrQ0I1DEs5JToNv9aeBkAop2k1Wt+Y0E2SccjpirCt5bZVcY5HvSYywGGAu1QeyjtSx5CnBBYnjtUAyJFBJ7k46KPc0+IkuwUHrwPWkMsqwKqCCwHVlH8vaoTGRzgnPJA9akUsB5bqOR91elKBtTLkZ6YXt9KQIagYybQMADI7ZoDGIEuOnQDvml2OoAGB6seuKdGPnDbcDqD0z70CkyWOM4bKtknPPTHpTdzSBh5IPORKzdPZR3qUhRH8745yPf2pkrhWG3BYjoef0/rTsc7ZSulX5z/D0+bq3f86hihwFboo/g9CelTs+XVh8wX24Jo+Q7ghPBxjvQKzsRby21WXhWwefwp3l7idr7RkcDtSoQcFgevGe/wDk0xXGTnO8Z47GkEUOMv7piAEA6CmPIGTG/CgbmJ70hG9yDy+DlQOgHU01plACKgyOy9B60BylW+kIQmLnHHPT2plsS42Z3gDIx275qy8aSuwYjy14CDoT7n0o8oHKquYyRyKBOy0GpulTKg7Ad3Axj3pjz+WxJ/75x+ePeppkKKPNPHUAH/PNQmNWdJJXwAeeOvvTFYatwhclQNzcFjxj/wCvT4SRwSAD6jH50z7KItznODzz1yelWEiDxg7SRxj1HtSGaGmBZrtYpJZo02tIyRtjOBkgfWr8q2ktsxgW5Ej2huIw85I4OCMdyP1rO0SDOqReXI8ZQM+5euFGeB61ctJ5LuyvrdJZF+VpVJ2kBcglTxkZ/nVrYymtbowQVAGSc/TrRVwBOkgCsOMUVJrdnKupIDZ6D86Z/DkDmnzgDk8VGMAjdwvtXScXQFJzhulPIBwenpzSMFVcqQ2R0poxhfUcGqaIT1JVwAu07j3ppIP3W79SaTIVvmOF7EUwqPKLZGAcFT1FSaJkoICljgjGKkWUlzsyM9qrEYAIxz2pVfH19BSZqi0jBUYnnAwBimq52/N86dlzSKwIyAwGelO4Bxj34FQaxkLbjGC4LD+6DjP41cjOEKsCcDlf61FNDsm2FSjD1GffNSwzlsKV3MeC2KTNOa+pMVK4Ck5xwo7D1zUQ+6WVctnqe1SOwQ4yMng+5pUORsC5z3xzSsaxloEZBAYnAJxz1qwEUEY3YP8Af70xEUqwzwOR/wDXp8T5LO6sBj6fSgOa5IigKpkUHHOAOB+FPSUFuOSV6IOPxNRKqvG3lEqAcnJ60rSKASUHzDHHGPf+lSUhWMuAqkZHUdjViDcyblIzg5Y9qpIwA3E5LevT8qtxKCokBIA6dhUmj2LCbY1UdSRksakRo485+UYLZbsarnhCzEjIxuNTf8sMY+fHUjoPWgzY/eXUEfNxyT2oJVVRi25+4I6VCZFCAFuh5wKN/wAoOQcdBQD2LDyMTluW7Eiqdw6ku24HOB16+1PaXOQcYPGAapSgySFn6DkD0pmNtSJZN7EO+2IcORwSM9vSrKlsMIRhSQFz1Iqq6ou87VZmI6c4qfJBG1sZB5B5FIuXkOlBwCpJI6ZPAFMcyEBWGQRwRximxE7DGwGzOf8ACpA44PPOVIzQTsRxsFAVMBiMZFCgrE7cFV2k4PPXFNCbUYgkscfn71WdnKgnjLYx68/yoGPnYqwzjnG4Y6+9XCS9ucjaueF7fhURicFAAM5yTnjr/jU4TADAHd1x2AoJlqQFGYgqCzdWDdvpSXIUjHmAgH07f408MY5A8fLAdP602Ebt24hQDk8Zyf8AHFMnZE1u3CB+Tt4Ppz0qcxbEc5wepPPFV4R+54RiRycnGammleaZACd23AXPIPvSEx+nCIzROtxKkysS/lqSyehHPJ9q17qcS28qpeTOCM+WtoI/MPoxFUdHk+zalFKxEOQ25uynGAT361qrdahbx3BuNRjdihWNVlUsXJ4PHQe5q4mU9zBcAtkw5z6DNFXNTYfbpTbzJg4LFWwC2Bkj2zRU3KSurnESheQ5x9agXgEDndVk4kCpjrz71XkUqcdh2xXQcjGuDG/A/OlLFuwB9cUuQVzgH3NMDZYsTkDqCaq5Ngc5GQcgdaarDGfwHtQ+CMjORzimgDgkHHtRYaZLtPC55FOToVIAce3X2NM3bG3Lzg96eGYrxjjueSfrSsapjlU4XaD97PXkfSpxJjap4GSxJqvBKS438Hse4p/zFC2SQPepsaX11LLZ28kqxG4gd/enBhgYwT796ht5j1dxGo5Unpn0p0bDkscH1681JvHYsxuWRum1jnH/ANen2zqrj5goOQeODVaMksVbIx696mWQKzFcFT3x/KkWi2ysrqx4TGdtOcq6q2SD3z/KolKnB6L3HtT22sFKk4HGPahgmOOWXbyD2GO1Sxw5RwzgDGMEdT/nvSxHn3zyT1NSsFVlfcHAPTvipsPmIY4ggBJ+boSRnH0qxbsrIdyggcDNRMQGyCNp5AyeaQSfKCCR7mpNFqi2rqpZTsbAHOMYprOCRkE9sdKrHCqMnOT6U77R5u8KQXAIHoKBWfQkkVyc4Az0ApgAjzk49TSwuQSrEcDINQXJzjGSAcZPFINdg3DgDuc0yWQKWIHyDnk/zqMP8oKY54JaomBkkA64znP8X4UE2JVZiudvyHpz6+oqYlVAcDA6Z9qhETjad5ZievoP8alYbug3BRyTQIbGSxIGMHrTpNjR4Lc57dCKQLzkbcHsO1OEZYcNjjBHfFAWBCzLwwAzkA9DSSRq0wB7DGOlEK4BYAgDsOvtVtkBkEg2qG45HelcXUqhWUMecemelSLKdg43t1wfX1qSZAqFwx46jHX/AOvUNxyAAAiZ4z60agtRVZSXCqVVunqPWnwxkgr91M7hjmkTJlwVBHZR0zUjkqqFQd3Uhc4+lMTXQRGkI2IhZwcKx5OPYVJjYV2lDKVw3qDSBxvJT7wXPUj/APXRGiCTeC2ckuf6UzNl7Sds2oxrOU5BG1jgFgPlBz71blW+ktbp9WtlVFjJQmMIyvngLjr9KywheQjaXOM7iCeM1atIPP8AP+07ynku6Ek8MOmB/SmiJLqVo5I1XB2Ke4OAaKrTTbXw8YVgOdwGT70UjTlOVDMvJx9RSn5jzTiNymm/w/Nx2roOQjII4bp2pD94c5X0pZWzwpyAMdO9AxxTREiNuMY59aM7hwe+SDTiBgFD8p6560wdRVEoe55wBuA6UoAwDnHqKRV3H5eT6UpPseP84pFp2GgjA+UlQM5qeMEs67uCMZHNQkH/AID6470pO0kLU7GiYSJuCAjBPIp8O4ZBP5Uu8v8AMAQwHPqTU2EJCvhZV4bjqaTRtGpZWFEuWXeCcHOD0NTwfMxwNoHr/IVWGCuRwegHrTxNjG4EkcHJyfwqbGid9i8pMRIUnLckdQKkhYGU8kFjj61XEm4AMRk85HanxsYwGCEuPu9vxNIZaaRARtyVPXH9aXzBuwMhSPy/GoY5BsYEgep55pVY5wSCBjO0UmUiVmJwQ3C8ZPekL/OFLEtj+H0pFkTuGyPQU5Rk4BC88kjBqDRMU5ACjgds9/enQlVLj5uRhsdfpUajbkNgsemDUyDOQwOM5AHc+9AOQ0Nl9oyBjPFKy8ZHf0pHJfjoOnHX61EzbSCpJyPrj8aBbkpCRqeFLHoPSomAAJAGT6Gjcpx8px196GQsQCVJ6letBD0GBmdjgA44qTaTjnjGMDpTUjCrhTnJ6enuae4KZBII6cGkCY47QduQO2PSnjJP7sDGOSah3ZY4XoakQnIBGB7UFtEqYAG/hhzgelO3q0QfjIIx6VDI2Dux7YHpShmKHgKOnJ6AUieXqSMzjgjBDcNQFjOFdc5525xn0qNpAQDyp7//AF6SNyW4DBccE96Y7Fm0bbI+SjMowQRwBTpEJIHmEofvMP0FUkk5KH5JM/N71MxO0xupCL1HqfehENaj1g3IViUqCcjd1/Gns3kx+WELOeSvXn1poc9ZcqcZVSeMetOm3R+W2QkjDcCeCfemT1Ldrf3Vtbhba7ljGSzR9Mn8vSpW1G8mjMb3UjeYCDE+OQfSk037I0MwuYWMmC6s0hXf7YHT2PelNxYyQkJYMkhXALTnIPY+9MnS+xnH5DtjBwP7yAmipXbbgMiOQOrHJooL1OQwVYZ49jSOck85qaXkcYJBz1qEgKOR7mt0cMgRowvIOc8j3qM4z16U5kzyTwf5UMinj8iKogaUwCMDpx7UjJzkjHbipfL2nBYEDuKGQ5xgtnuP5UydmVzkHOfoacVLNxnb1NK46hu9RqWVgQ3PoelBZIjMyYJ4z16U18ggYz9BSM3RP4iO/c08SZOD8uB3qR3BGIIVlJ9MVIcHO7O0Dgnkio1+UhtxUjkYpQx3uWBxjsOMUFJljIAwSR3NJ99ssDkc4qEDvksO+Tin7iEzkHA7dRSaNIysTgqWCr+GKe0pVsrzjjDHOarFldOPlPsakiPDBz8uOAB1NQbqXUs+ahAAXBx3NKrlzjds+vWqYcGTOOnBA6gVZ3BmAO09+B1qXqaJotRuwGYyQQ3btUm9VkGW3N3z0qBJBG3yHn1/pSEeZwo49u9SylItBiSCFHPUjPFSB2UDjP8ASoQ+xFJbBA6NzUXmtI+3cwNOxN7lpivmdC3GAvT9KjYljj5SF7+lNKYPHHGM+tSDyxjH059aQ7iR5Df73fvj2FOBUcnpnGBTWbAOev6iljOPugbR8vSglskHzgY4Hp0pwA5Eh5GOKjJ24Ukgeg60+RsdeEPY9TSEtRHG3+I+5A6UAnGRnr1Hemc7sAZbrgU/IIYcDFKxYz5nyNhApEA2kA8+o5p5KlRj8eacNuw8hSfQUFXGFVxkjt+dLErA4Kk8cse1OJ+U+ncZ701QzNlgQDxgc5oEwRcEYweM08oFkBYjYVwMnGKBhCCRj296a5Bbdnkd++KESiwzIzKB80o6beMinCNsnc2ZOm5ucVBDsI4A3ueCT+VTJlQ8XLZOT6GmJo2NOtYbu3meaadZol3NtAIZB1xnrUDtpzMGSa9kmxmMPCoBPvzT0EUNqtxdpM4eQxrDG+FBUdWP48U4x2c8dwbVJo7iNS/L7wQOceq/WqsZdSk7KpxIibsdlzRVco0hLP8AOx6ktRSLsc3gYJbgjt7VGBnO7t1qVkPJHIpVBEbgrkEgk1sjkkQtgqcYx2FIzEsDtC8c470rrtB29fWmupdhjAOeD/SqM7CBgNuOnUf/AF6c5ypznBOc9KYTjG7IKnGMUqgkdMgdaYrEe0HJOfUVGyEgk8A9Knbn7oz7U3kH9cUDIY93lksVIHGD1FPBzsHt19abIhy3HBpSpZMEjHqOxoYEow67T35/3fxpr5XaQGwcgDNNY7UKsTkcggcGmhmJ6kjGOKYkOBycDI7Y6Uq7s5BHHepEkjyRySwwS3GKhOUJyVYHHA5I+lJotSJPNUHcF+YnNL5oB6Hnnd6VGHAkDc5z3ppc5AJGec47Umi4ydy0gUxgg5HU9j+VTpIEjWBMBN+8YHJb61nopXLRHg+tTRtghweex9Kho2Uu7LyuQdx698c05Zt2OdpJ6D0qqHUYL5ZS33emaQMuCCxwP8aVh8xc83CsEYc+lKjsFDEbuPxNU0kVWXf0J6jkj3qZJVIyQcD1PSlYfOWhIQeeQRnApxZhgNhcrxx8w9qp7yEDAggc/hTjMzgqAQR3JpND5izvXGCCc9MmnQM24hwc+g4FV42L8kgDHbtU2Cg5wOR1OaVgbLeMk7lAYjjBGB+PrUcmPq+evr+FROygmMAs2c5zxTfOPmbWYnjHAptAnZhI5ijO3P160sbyAAsCM9sUMSRtOFIAwKavHQ4x3z1NQzVMsKFZSG5bvSgEZYHqBVdWc8cDrk09XLZwcZ6ZoAlYMcY6E5pu9k+YDK9wOKcrMcAEHBycUoVi3zYA9PakDYqSBwcJye3pQCysfXqaaFyxK59KazYbIOSeg6UXBK+hJGS0nJAHoBiriklWG3CYwD1INU0CsRg+xz2NWEICqpyQTxTQpI29EMtqkkjXyW9s5MYDJ5m9wOeO2M1JcLeym5ju544YI4zMBCigSKCMcjrWdHfGC1e2ZEkViWTIxsPcipLbUZYNOlgmCSoyMqFvvJn09vUVaaM+Rt3KBVC7McsGOQcdqKvJHGI185izEZyozRS0NbnKsABx19KZMjdANv8AjU4Cs43HGePxpZMk/McMvA961OFlXGCQRgDn6VG2CpG7bnjJHBqw3zuNwBJ/nTWXcMA5HQA9qoloplD83OQDwe9SRlXLDIDdR6U9oSxwW4Wq5RwSCfxoFa+hO20bmGeR09KDGMDcuP600EN99ie1PfcYgFIO3pVXJaINpVhv6HmmkgDcSQB/FipiGZAXwaGHJGenbt+FAipsIJAIK4704oSTgkfL9Kc0Z6ZzjmnspEfy4wOTxQA1iAmfL+X27+1Iz75V5RcKBhehpWUNlY8rxk0hOAMLggfe71RA2bMjk7QvYgdKDtYKQcMevHQ1MiErhvnYnoaj8sq77dxxxt60WBSYwEsu3IXnGccmmnfjkjfnjParM8oAXZECAQO3TvmopU/diRThDxhup96mxSqMjDFGBBwen41bLxoiqwZjjcT0xn0qpIgOMb2A/X1pMqsewqCc5z16UrFudx5L5BQBhjGOhp6uMrk4I71FvG/c24p2z0o+VmBYnJ7dhSsNSJ5JOQQfwqRXyP5Zqq2EYjg57jvT1mKOueePwxUtGimX4cfebGc45/nTicuw3Hk5z/hVBZSwIU7eehqVZem8Y69O9Kw+YvIR0ZDx78n3p6n5MN8uOmapC4wScZJ6YNWIpCGVsBj1H+FKxdyZuV+YYX+dKAcJsAb1PBI9PpUJl3lgx+8eQtPRtq7V6ipsVzWJxwp3tkjoAOKaUy2W+6wyGJ5/KkiOWwBtYdx3/GnswwApG4HGKTRakSpgYwCVI9OlPR0XBxuyPTjFQqR5ez+Lrk0jM7H5jnPTikxp3LBwVHfFV3J3LnAwew6U/dx2z6im7ORSKTsPALyAqAfUZ61NuZMDkhh6dKqufLB2DOOuD1qZGLIQQMnk0F7q5q6cpt7V7olTKyOS5TfsVcDhemSSOewq1t+3WnmT7DOUYLIUClCo3YyOqkH8DWfpd6LdRHKWCZJR0ILISMEYPBB7g+lWLjU1aBoIvMckbS7BU2rnkKo457mqRDi7kCR25X/SGkDDgY6Yoqo8gJyRk+uaKk1sf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and telangiectasias are present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40186=[""].join("\n");
var outline_f39_15_40186=null;
var title_f39_15_40187="Clinical manifestations of Fabry disease";
var content_f39_15_40187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of Fabry disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Childhood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain, numbness of fingers and toes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telangiectasias on ears, conjunctiva",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blue-black angiomatous macules or papules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edematous upper eyelids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raynaud phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthamologic abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Early adulthood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensive telangectasias, angiokeratomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albuminuria, hematuria, oval fat bodies in urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever, heat collapse, anhidrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphadenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        30-40 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac disease: coronary conduction defects, mitral insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular attacks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic findings suggesting multiple sclerosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 2004; 19:583. Copyright &copy; 2004 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40187=[""].join("\n");
var outline_f39_15_40187=null;
var title_f39_15_40188="Conditions assoc high amylase";
var content_f39_15_40188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with a high serum amylase",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pancreatic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pancreatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Complications of pancreatitis (pseudocysts, abscess)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ERCP",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ductal obstruction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pancreatic carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cystic fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Salivary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ductal obstruction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gastrointestinal disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Perforated or penetrating peptic ulcer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Perforated bowel",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obstructed bowel",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mesenteric infarction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Appendicitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cholecystitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Liver disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe gastroenteritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Celiac disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gynecologic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ruptured ectopic pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ovarian or fallopian cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pelvic inflammatory disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Neoplasms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Solid tumors of the ovary, prostate, lung, esophagus, breast and thymus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple myeloma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pheochromocytoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Macroamylasemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Burns",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acidosis (ketotic and non-ketotic)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AIDS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cerebral trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abdominal aortic aneurysm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anorexia nervosa, bulimia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-operative",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Drug induced",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Following double-balloon enteroscopy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute liver failure",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40188=[""].join("\n");
var outline_f39_15_40188=null;
var title_f39_15_40189="Contents: Bullous disease";
var content_f39_15_40189=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Bullous disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Bullous disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/11/22714\">",
"           Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/34/35369\">",
"           Dermatitis herpetiformis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/58/15273\">",
"           Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/47/4858\">",
"           Epidermolysis bullosa acquisita",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/38/42601\">",
"           Initial management of pemphigus vulgaris and pemphigus foliaceus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/36/14922\">",
"           Linear IgA bullous dermatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/43/3770\">",
"           Management and prognosis of bullous pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/39/39544\">",
"           Management of mucous membrane pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/12/26825\">",
"           Management of refractory pemphigus vulgaris and pemphigus foliaceus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4138\">",
"           Ocular cicatricial pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/44/18121\">",
"           Paraneoplastic pemphigus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/44/19146\">",
"           Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-C2202D2A1A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f39_15_40189=[""].join("\n");
var outline_f39_15_40189=null;
var title_f39_15_40190="Energy requirements of infants";
var content_f39_15_40190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Energy requirements of infants, FAO/WHO/UNU",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 386px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Energy requirements of healthy infants 0 to 12 months of age as estimated by the joint FAO/WHO/UNU Expert Consultation on Energy in Human Nutrition in 2001 (closed symbols), combining data for breastfed and formula-fed infants. The 1985 FAO/WHO/UNU estimates are shown for comparison (open symbol).",
"    <div class=\"footnotes\">",
"     FAO: Food and Agriculture Organization of the United Nations; WHO: World Health Organization; UNU: United Nations University.",
"    </div>",
"    <div class=\"reference\">",
"     Food and Agriculture Organization of the United Nations, 2004, Human energy requirements: Report of a Joint FAO/WHO/UNU Expert Consultation. Food and Nutrition Technical Report Series 1,",
"     <a href=\"file://www.fao.org/docrep/007/y5686e/y5686e05.htm\" style=\"font-style: italic;\" target=\"_blank\">",
"      file://www.fao.org/docrep/007/y5686e/y5686e05.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40190=[""].join("\n");
var outline_f39_15_40190=null;
var title_f39_15_40191="Squamous cell carcinoma skin";
var content_f39_15_40191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Squamous cell carcinoma of the dorsum of the hand appearing as a firm, keratotic nodule in a patient who has undergone liver transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean-Fran&ccedil;ois Dufour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_15_40191=[""].join("\n");
var outline_f39_15_40191=null;
